,index,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,arms,arm1,arm2,arm1_included,arm2_included,arm1_to_remove,arm2_to_remove,also_arm1_to_remove,also_arm2_to_remove,new_arm1,new_arm2,arm1_has_approved_drugs,arm2_has_approved_drugs,Included,Reason
2,21,22,NCT00553800,Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer,NSCLC,Unknown status,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: bevacizumab|Drug: Erlotinib,Efficacy measure is progression free survival defined as the time from enrollment to documented progression of disease by radiologic imaging.|toxicity,"Fox Chase Cancer Center|Genentech, Inc.|OSI Pharmaceuticals",All,70 Years and older   (Older Adult),Phase 2,33,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FER-TH-007,7-Mar,13-Oct,17-Apr,6-Nov-07,,5-Feb-16,"AtlantiCare Regional Medical Center, Galloway, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Memorial, Mount Holly, New Jersey, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Abramson Cnacer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Grand View Hospital, Sellersville, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00553800,2,bevacizumab,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,bevacizumab,erlotinib,1,1,TRUE,
9,49,50,NCT00048087,Iressa/Docetaxel in Non-Small-Cell Lung Cancer,,Withdrawn,No Results Available,Non-small Cell Lung Cancer,Drug: ZD1839|Drug: Docetaxel,Patient Response Rate to Iressa/Docetaxel,M.D. Anderson Cancer Center|AstraZeneca|Aventis Pharmaceuticals,All,"Child, Adult, Older Adult",Phase 2,0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID02-004,2-Aug,3-Jul,3-Jul,25-Oct-02,,31-Jul-12,"UT MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00048087,2,zd1839,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,iressa,docetaxel,1,1,TRUE,
29,145,146,NCT00434668,Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer,TOLEDO,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: cisplatin/docetaxel|Drug: cisplatin/vinorelbine,Success of delivery treatment; data collected during chemotherapy treatment|Toxicity (occurrence of any grade 4 toxicity); data collected at the end of each cycle|Overall toxicity|Progression free survival and overall survival,"University Hospital, Antwerp|Universiteit Antwerpen|Sanofi",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,99,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOGA 0501|Eudra CT 2005-004029-24,5-Dec,10-Sep,10-Nov,13-Feb-07,,30-Nov-10,"ZNA Middelheim, Antwerpen, Antwerp, Belgium|University Hospital Antwerp, Edegem, Antwerp, Belgium|St Augustinus ziekenhuis, Wilrijk, Antwerp, Belgium",,https://ClinicalTrials.gov/show/NCT00434668,2,cisplatin/docetaxel,cisplatin/vinorelbine,1,1,FALSE,FALSE,FALSE,FALSE,cisplatin/docetaxel,cisplatin/vinorelbine,1,1,FALSE,Cisplatin is not an approved drug
42,190,191,NCT02521051,"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",,Recruiting,No Results Available,Non-Small Cell Lung Cancer (NSCLC),Drug: Alectinib|Drug: Bevacizumab,"Recommended phase II dose of the combination of Alectinib and Bevacizumab|Number of participants treated with the combination of alectinib and bevacizumab with adverse events|Central nervous system objective response rate|Central nervous system disease control rate|Central nervous system progression-free survival|Overall objective response rate|Overall disease control rate|Progression-free survival|Quality of life: change from baseline to on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30|Quality of life: change from baseline and on-treatment, measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-BN20|Number of patients with an ALK resistance mutation","Massachusetts General Hospital|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,43,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-055,15-Oct,19-Oct,22-Jun,13-Aug-15,,28-Feb-19,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02521051,2,alectinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,alectinib,bevacizumab,1,1,TRUE,
55,229,230,NCT00769067,A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen,,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: PF-00299804,Progression-Free Survival (PFS)|Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13)|Dermatology Life Quality Index (DLQI)|Percentage of Participants With Objective Response|Best Overall Response (BOR)|Duration of Response (DR)|Overall Survival (OS),Pfizer,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,188,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A7471028|2008-005235-14,8-Nov,10-Oct,14-Aug,8-Oct-08,21-Aug-15,7-Oct-15,"Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Agajanian Institute of Oncology and Hematology, Montebello, California, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Wittingham Cancer Center @ Norwalk Hospital, Norwalk, Connecticut, United States|Medical Oncology & Hematology, P.C., Waterbury, Connecticut, United States|Winship Cancer Institute at Grady Health Systems, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Augusta Oncology Associates, P.C., Augusta, Georgia, United States|Augusta Oncology Associates, PC, Augusta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|The Longstreet Cancer Center, Gainesville, Georgia, United States|Central Georgia Cancer Care, P.C., Macon, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|Central Georgia Cancer Care, P.C., Warner Robins, Georgia, United States|Kootenai Cancer Center at Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Center for Blood and Cancer Disorders, Bethesda, Maryland, United States|Associates in Oncology/Hematology, PC, Rockville, Maryland, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|The West Clinic, Memphis, Tennessee, United States|Oncology/Hematology Associates, Clarksburg, West Virginia, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|The Andrew Love Cancer Centre,, Geelong, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|FUNDACAO PIO XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Department of Clinical Oncology, Shatin, New Territories, Hong Kong|Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea, Republic of|SamsungMedicalCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine, Seoul, Korea, Republic of|Medex spolka cywilna, Chrzanow, Poland|¿KardioDent¿, Krakow, Poland|""Vesalius"" Sp. z o.o., Krakow, Poland|Zaklad Rentgena i USG Wyrobek spolka jawna, Krakow, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Niepubliczny Zaklad Opieki Zdrowotnej AVI Centrum Medyczne, Warszawa, Poland|Ponce School of Medicine / CAIMED Center, Ponce, Puerto Rico|National Cancer Centre, Singapore, Singapore|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Teresa Herrera, La Coruña, Spain|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Chest Department, Taipei, Taiwan|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00769067,2,erlotinib,pf-00299804,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,dacomitinib,1,1,TRUE,
71,308,309,NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Ceritinib|Drug: Trametinib,"Maximum tolerated dose (MTD) of the combination of ceritinib and trametinib in advanced ALK-rearranged, or ROS-1 rearranged NSCLC, by number of Adverse Events (AEs)|Overall response rate (ORR) with combination ceritinib + trametinib in patients with Stage IIIB or IV ALK-rearranged NSCLC|Disease control rate (DCR) with combination ceritinib + trametinib in patients with Stage IIIB or IV ALK-rearranged NSCLC|Progression-free survival (PFS) with combination ceritinib + trametinib in patients with Stage IIIB or IV ALK-rearranged NSCLC|Overall survival (OS) with combination ceritinib + trametinib in patients with Stage IIIB or IV ALK-rearranged NSCLC|Time to central nervous system (CNS) progression with combination ceritinib + trametinib in patients with Stage IIIB or IV ALK-rearranged NSCLC|Peak plasma concentration (Cmax) of ceritinib + trametinib","University of California, San Francisco|Novartis Pharmaceuticals|University of California, Davis|University of California, Los Angeles|University of California, San Diego|University of California, Irvine",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,69,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CC# 166512,9-Sep-17,20-Mar,21-Mar,22-Mar-17,,24-Oct-18,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT03087448,2,ceritinib,trametinib,1,1,FALSE,FALSE,FALSE,FALSE,ceritinib,trametinib,1,1,TRUE,
82,348,349,NCT00430651,Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC),,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Docetaxel|Drug: Carboplatin,Comparison of the overall survival between the two treatment groups|Comparison of the objective response rates between the two treatment groups|Evaluation and comparison of the toxicity between the two treatment groups|Measurement and comparison of the health-related quality of life of patients on both treatment groups,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,135,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/04.14,4-Jul,8-May,8-May,2-Feb-07,,28-Jan-09,"University Hospital of Crete, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""IASO"" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|""Sotiria"" General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases, Athens, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|""Metaxa's"" Anticancer Hospital of Pireaus, Piraeus, Greece|""Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00430651,2,docetaxel,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,carboplatin,1,1,TRUE,
102,403,404,NCT03801304,Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,VinMetAtezo,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Atezolizumab|Drug: Vinorelbine,Occurrence of death or progression of the disease|Emergence of adverse events (Safety and tolerability)|Occurrence of death|Objective Response Rate|Following of the quality of life,"University Hospital, Brest|Groupe Français de Pneumo-Cancérologie|Roche Farma, S.A|Pierre Fabre Medicament",All,"18 Years and older   (Adult, Older Adult)",Phase 2,71,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,29BRC18-0005 (VinMetAtezo),24-Jan-19,24-Jul-20,24-Jul-22,11-Jan-19,,24-Oct-19,"CH Aix en Provence, Aix-en-Provence, France|CHRU de Brest - Hôpital Morvan, Brest, France|CLCC Caen, Caen, France|CH de Créteil, Créteil, France|Ch La Roche Sur Yon, La Roche Sur Yon, France|CHU de Limoges - Hôpital DUPUYTREN, Limoges, France|CH Lorient, Lorient, France|CH MEAUX, Meaux, France|CHU Montpellier, Montpellier, France|CH Pringy, Pringy, France|CH Quimper, Quimper, France|CHU de Rennes, Rennes, France|CHU Rouen, Rouen, France|CH Saint-Brieuc, Saint-Brieuc, France|Hia Saint Anne, Toulon, France|CH Villefranche sur Saône, Villefranche-sur-Saône, France",,https://ClinicalTrials.gov/show/NCT03801304,2,atezolizumab,vinorelbine,1,1,FALSE,FALSE,FALSE,FALSE,atezolizumab,vinorelbine,1,1,TRUE,
103,404,405,NCT00741221,Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer,,Completed,No Results Available,Non-small-cell Lung Cancer,Drug: Pemetrexed|Drug: Bevacizumab,Progression Free Survival|Overall response rate|Overall Survival|Quality of life assessment|Toxicity profile,Hellenic Oncology Research Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/08.10,8-Jun,16-Oct,16-Oct,26-Aug-08,,4-Oct-16,"University Hospital of Heraklion, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO"" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|Sotiria"" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|""Metaxa's"" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00741221,2,pemetrexed,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,bevacizumab,1,1,TRUE,
111,424,425,NCT00741195,Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer,,Completed,No Results Available,Non-small-cell Lung Cancer,Drug: Docetaxel|Drug: Bevacizumab,Progression Free Survival|Overall response rate|Overall Survival|Quality of life assessment|Toxicity profile,Hellenic Oncology Research Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/08.09,8-Apr,16-Oct,16-Oct,26-Aug-08,,4-Oct-16,"University Hospital of Heraklion, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO"" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|Sotiria"" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|""Metaxa's"" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00741195,2,docetaxel,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,bevacizumab,1,1,TRUE,
115,440,441,NCT02730247,Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: ramucirumab|Drug: nab-paclitaxel,Progression-free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|EuroQol Five Dimension questionnaire (EQ-5D-5L) score,"Liza Villaruz, MD|University of Pittsburgh",All,"18 Years and older   (Adult, Older Adult)",Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-169,5-Jul-17,8-Sep-19,8-Sep-19,6-Apr-16,,16-Sep-19,"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02730247,2,ramucirumab,nab-paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,ramucirumab,nab-paclitaxel,1,1,TRUE,
121,457,458,NCT02613507,Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer,CheckMate 078,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: Nivolumab|Drug: Docetaxel,Median Overall Survival|Overall Survival Rate|Objective Response Rate|Overall Survival in Subpopulations|Median Progression Free Survival (PFS)|Progression Free Survival Rate,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,639,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-078|2015-001893-16,10-Dec-15,15-Sep-17,19-Feb-20,24-Nov-15,22-Feb-19,21-May-19,"Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Hong Kong, Hong Kong|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02613507/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02613507/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02613507,2,nivolumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,nivolumab,docetaxel,1,1,TRUE,
123,463,464,NCT01066195,Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,,Unknown status,No Results Available,Non-small Cell Lung Cancer,Drug: iressa|Drug: alimta,progression-free survival|overall survival|objective response rate|toxicity,Samsung Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 3,129,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-04-030,8-May,10-Oct,,10-Feb-10,,10-Feb-10,"Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01066195,2,iressa,alimta,1,1,FALSE,FALSE,FALSE,FALSE,iressa,alimta,1,1,TRUE,
130,487,488,NCT02075840,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,ALEX,"Active, not recruiting",Has Results,Non-Small Cell Lung Cancer,Drug: Alectinib|Drug: Crizotinib,Progression-Free Survival (PFS) by Investigator Assessment|Percentage of Participants With PFS Event by Investigator Assessment|PFS Independent Review Committee (IRC)-Assessed|Percentage of Participants With PFS Event by IRC|Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria|Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria|Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria|Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators|Overall Survival (OS)|Percentage of Participants With OS Event|Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria|CNS DOR IRC-assessed According to RECIST v1.1 Criteria|Percentage of Participants With Adverse Events|Area Under The Concentration-Time Curve (AUC) of Alectinib|Maximum Concentration (Cmax) of Alectinib|Time to Reach Cmax (Tmax) of Alectinib|AUC of Alectinib Metabolite|Cmax of Alectinib Metabolite|Tmax of Alectinib Metabolite|Time to Deterioration by European Organization for The Research And Treatment of Cancer (EORTC) Quality Of Life Questionnaire Core 30 (C30)|Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30)|Time to Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)|Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)|Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest|HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,303,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO28984|2013-004133-33,19-Aug-14,9-Feb-17,29-Sep-22,3-Mar-14,15-Mar-18,10-Oct-19,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States|Moores UCSD Cancer Center; Dept Clinical Trials Office, La Jolla, California, United States|Long Beach Memorial Medical Center; Oncology, Long Beach, California, United States|North Valley Hem Onc Med Grp; Thomas&Dorothy Leavey Can Ctr, Northridge, California, United States|Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|TMPN/ Cancer Care Associates, Redondo Beach, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|University of Miami-Deerfield Beach, Deerfield Beach, Florida, United States|Cancer Institute of Florida PA, Orlando, Florida, United States|Memorial Health Care System, Pembroke Pines, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington Uni School of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Center - Peak, Las Vegas, Nevada, United States|Columbia University Medical Center, Bronx, New York, United States|St. Lukes Hospital and Health Network, Bethlehem, Pennsylvania, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University of Pittsburgh Medical Center; Division of Hematology-Oncology, Pittsburgh, Pennsylvania, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Queen Elizabeth Hospital; Medical Oncology, Woodville South, South Australia, Australia|Monash Health Translational Precinct; Clinical Trials Centre, Level 3, Victoria, Australia|University Clinical Centre of the Republic of Srpska; Clinic for Pulmonary Diseases, Banja Luka, Bosnia and Herzegovina|University Clinical Center Sarajevo;Clinic for Pulmonary disease, Sarajevo, Bosnia and Herzegovina|University Clinical Center Sarajevo;Institute of oncology, Sarajevo, Bosnia and Herzegovina|Centro de Pesquisa Clínica- Instituto do Câncer do Ceará- ICC, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Moncton Hospital, Moncton, New Brunswick, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Mount Sinai Hospital; Oncology, Toronto, Ontario, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Centro Internacional de Estudios Clínicos (CIEC), Santiago, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Sun Yet-sen University Cancer Center, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|Clinica CIMCA, San Jose, Costa Rica|Kasr Eieny Uni Hospital; Oncology (Nemrock), Cairo, Egypt|Nci; Oncology Dept, Cairo, Egypt|Centre Georges Francois Leclerc, Dijon, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique, Marseille, France|Hopital Tenon;Pneumologie, Paris, France|Hopital Haut Leveque, Pessac, France|Hopital Pontchaillou, Rennes, France|St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie, Karlsruhe, Germany|Klinik Löwenstein gGmbH Medizinische Klinik II, Löwenstein, Germany|Uoa Sotiria Hospital; Oncology, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Grupo Angeles, Guatemala City, Guatemala|Pamela Youde Nethersole Eastern Hospital; Clinical Oncology, Hong Kong, Hong Kong|Princess Margaret Hospital; Oncology, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Medical Center; Oncology, Haifa, Israel|Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Belinson Medical Center, Division of Oncology, Petach Tikva, Israel|Assaf Harofeh; Oncology, Zerifin, Israel|Azienda Ospedaliera S.G. Moscati; Division of Medical Oncology, Avellino, Campania, Italy|Seconda Universita' Degli Studi; Divsione Di Oncologia Medica, Napoli, Campania, Italy|A.O. Universitaria Di Parma; Oncologia Medica, Parma, Emilia-Romagna, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico, Orbassano, Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica, Catania, Sicilia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Instituto Nacional De Enfermedades Respiratorias;Unidad de Investigación, Mexico City, Mexico|Uni of Auckland; Medical School, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Ms Clinsearch Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej, Lublin, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Med.-Polonia Sp. z o.o. NSZOZ, Poznan, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warszawa, Poland|Hospital Geral; Servico de Pneumologia, Coimbra, Portugal|IPO de Lisboa; Servico de Pneumologia, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|City Clinical Hospital No. 1, Novosibirsk, Russian Federation|Medical Radiological Research Centre Rams; Dept. of Radiotherapy & Chemotherapy of Hemoblastosis, Obninsk, Russian Federation|SPb City Clin Onc Dsp; Chemotherapy, St. Petersburg, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia|Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, Spain|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Inselspital Bern; Universitätsklinik für medizinische Onkologie, Bern, Switzerland|CHUV; Departement d'Oncologie, Lausanne, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan|National Cancer Inst., Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Chiang Rai Prachanukroh Hospital; Department Of Medicine, Chiang Rai, Thailand|Khonkaen Hospital, Khonkaen, Thailand|King Chulalongkorn Memorial Hospital; Faculty of Medicine Chulalongkorn University, Patumwan, Thailand|Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory, Songkhla, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Ankara University Medical Faculty; Medikal Onkoloji, Ankara, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|Dnipropetrovsk State Medical Academy; Chemotherapy Department, Dnipropetrovsk, Ukraine|Karkiv Regional Oncology Center, Kharkiv, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre; Department of hemotherapy, Lviv, Ukraine|Birmingham Heartlands Hospital; Dept of Oncology, Birmingham, United Kingdom|University College London Hospital, London, United Kingdom|Guys & St Thomas Hospital; Department of Oncology, London, United Kingdom|Royal Preston Hosp; Rosemere Cancer Ctr, Preston, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02075840/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02075840/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02075840,2,alectinib,crizotinib,1,1,FALSE,FALSE,FALSE,FALSE,alectinib,crizotinib,1,1,TRUE,
135,514,515,NCT01020786,A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients,,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Carboplatin,"Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods|Overall Survival (OS) During the Induction and Maintenance Therapy Periods|Percentage of Participants Who Achieve a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction and Maintenance Therapy Periods|Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) During the Induction and Maintenance Therapy Periods|Progression Free Survival (PFS) During the Maintenance Therapy Period|Overall Survival (OS) During the Maintenance Therapy Period|Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Maintenance Therapy Period|Percentage of Participants Who Observe a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction Therapy Period|Percentage of Participants Who Achieve a Complete Response (CR) or a Partial Response (PR) During the Induction Therapy Period",Eli Lilly and Company,All,"20 Years and older   (Adult, Older Adult)",Phase 4,109,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12628|H3E-JE-JMII,9-Nov,11-Mar,12-Jun,26-Nov-09,16-Mar-12,27-Aug-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan",,https://ClinicalTrials.gov/show/NCT01020786,2,pemetrexed,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,carboplatin,1,1,TRUE,
137,525,526,NCT01196234,Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer,PRIDE,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Paclitaxel/Carboplatin/Gefitinib|Drug: Paclitaxel/Carboplatin,Response Rate|progression free survival|overall survival,Asan Medical Center|AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 2,84,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMC 2009-0677,9-Dec,12-Feb,12-Dec,8-Sep-10,,29-Jan-13,"Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01196234,2,paclitaxel/carboplatin/gefitinib,paclitaxel/carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,paclitaxel/carboplatin/gefitinib,paclitaxel/carboplatin,1,1,TRUE,
140,558,559,NCT00755170,Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Vinorelbine|Drug: Bevacizumab,Response rate|Toxicity profile|Progression free survival|Overall survival,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/08.18,8-Nov,16-Oct,16-Oct,18-Sep-08,,4-Oct-16,"University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""IASO"" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|401 Military Hospital of Athens, Athens, Greece|Air Forces Military Hospital of Athens, Athens, Greece|University Hospital of Crete, Dep of Medical Oncology, Heraklion, Greece|State General Hospital of Larissa, Dep of Medical Oncology, Larissa,, Greece|""Theagenion"" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece|Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00755170,2,vinorelbine,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,vinorelbine,bevacizumab,1,1,TRUE,
142,574,575,NCT00906282,"Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer",,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Carboplatin,3-Year Overall Survival Rate|Objective Tumor Response|Pathologic Response Rate|Rate of Residual Disease as an Assessment of Pathological Partial Response (pPR)|Complete Resection Rate,"SCRI Development Innovations, LLC|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 2,46,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LUN 186,9-Jun,15-Aug,15-Sep,21-May-09,24-Feb-17,24-Feb-17,"Florida Cancer Specialists, Fort Myers, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Virginia Cancer Institute, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00906282,2,pemetrexed,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,carboplatin,1,1,TRUE,
144,580,581,NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: pemetrexed|Drug: docetaxel,Overall Survival|Overall Tumor Response|Progression-Free Survival (PFS)|Duration of Response|Pharmacology Toxicity,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,211,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10717|H3E-MC-JMID,6-Oct,8-Dec,10-Jun,23-Oct-06,30-Mar-10,12-Apr-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nan Jing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tianjin, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China",,https://ClinicalTrials.gov/show/NCT00391274,2,pemetrexed,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,docetaxel,1,1,TRUE,
148,585,586,NCT00350792,Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients,,Completed,Has Results,Non Small Cell Lung Cancer,Drug: pemetrexed|Drug: carboplatin,Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)|Time to Treatment Failure|Overall Survival|Estimated Probability of One Year Progression-free Survival,Eli Lilly and Company,All,70 Years and older   (Older Adult),Phase 2,62,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9941|H3E-FP-S099,6-Aug,8-Nov,9-Nov,11-Jul-06,9-Dec-09,13-Oct-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bobigny, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brest, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT00350792,2,pemetrexed,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,carboplatin,1,1,TRUE,
150,598,599,NCT01903993,"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - ""POPLAR""",,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Docetaxel|Drug: Atezolizumab,Overall Survival (OS)|Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Duration of Response (DOR)|ORR (Modified RECIST)|PFS (Modified RECIST)|DOR (Modified RECIST),Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,287,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO28753|2013-001142-34,6-Aug-13,19-Nov-15,6-Sep-18,19-Jul-13,23-May-17,2-Oct-19,"Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Centers - Colorado Springs (Circle), Lone Tree, Colorado, United States|Ocala Oncology Center, Ocala, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|New England Cancer Specialists, Scarborough, Maine, United States|Karmanos Cancer Institute.., Detroit, Michigan, United States|Billings Clinic; Research Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|The Valley Hospital, Paramus, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Broome Oncology - Binghamton, Binghamton, New York, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Center for Biomedical Research LLC, Knoxville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Providence St. Mary Regional Cancer Center, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|UZ Leuven Gasthuisberg, Leuven, Belgium|Chr de La Citadelle, Liège, Belgium|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital Gabriel Montpied; Service de Pneumologie, Clermont-ferrand, France|Hôpital Nord Michallon; Pneumologie, La Tronche, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll; Pneumologie, St Brieuc, France|Hopital Larrey; Pneumologie, Toulouse, France|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Germany|Citta Ospedaliera; Divisione Oncologia Medica, Avellino, Campania, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Centre; Division of Hematology/Oncology, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Universitetssjukhuset Linköping; Lungmedicinkliniken, Linköping, Sweden|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Charing Cross Hospital; Medical Oncology., London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01903993,2,docetaxel,atezolizumab,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,atezolizumab,1,1,TRUE,
155,620,621,NCT00840125,Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: erlotinib|Drug: docetaxel,all cause mortality,Meir Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MG-NSCLC-2008,9-Feb,10-Dec,11-Aug,10-Feb-09,,30-Oct-12,"Meir Medical Center, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT00840125,2,erlotinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,docetaxel,1,1,TRUE,
159,632,633,NCT00550173,A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer,,Completed,Has Results,Non-Small-Cell Lung Cancer,Drug: pemetrexed|Drug: erlotinib,"Progression-Free Survival (PFS)|Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]|Overall Survival (OS)|Number of Participants With Adverse Events|Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)|Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)|Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status|Probability of OS at 12 Months",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,247,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10725|H3E-MC-S103,7-Nov,12-Jan,12-Jan,29-Oct-07,13-Feb-13,13-Feb-13,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanning, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sha Tin, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bhopal, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mohali, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vishakhapatnam, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jin-Ju-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poole, Dorset, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelmsford, Essex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00550173,2,pemetrexed,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,erlotinib,1,1,TRUE,
162,640,641,NCT00441922,Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Docetaxel|Drug: Vinorelbine,Overall survival between the two treatment arms|Time to disease progression|Toxicity profile,Hellenic Oncology Research Group|University Hospital of Crete,All,65 Years to 80 Years   (Older Adult),Phase 3,166,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/03.07,3-Jan,8-Jan,8-Jan,1-Mar-07,,29-Oct-08,"University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupolis, Greece|401 Military Hospital of Athens, Athens, Greece|Air Forces Military Hospital of Athens, Athens, Greece|IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens, Greece|Laikon General Hospital, Medical Oncology Unit, Propedeutic Department of Internal Medicine, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Department of Pulmonary Diseases, Athens, Greece|Sotiria General Hospital, 1st, 3rd, 8th Department of Pulmonary Diseases, Athens, Greece|State General Hospital of Larissa, Department of Medical Oncology, Larissa, Greece|Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology, Piraeus, Greece|Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00441922,2,docetaxel,vinorelbine,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,vinorelbine,1,1,TRUE,
165,645,646,NCT01121575,A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer,,Completed,Has Results,Non Small Cell Lung Cancer,Drug: PF-02341066|Drug: PF-00299804,"Overview of Treatment-emergent All Causalities Adverse Events (AEs) in Escalation Phase|Overview of Treatment-emergent All Causalities AEs in Expansion Phase|Overview of Treatment-emergent, Treatment-related AEs in Escalation Phase|Overview of Treatment-emergent, Treatment-related AEs in Expansion Phase|Number of Participants With Dose Limiting Toxicities (DLTs) in Escalation Phase|Number of Participants With Stable Disease and Stable Disease Duration in Escalation Phase|Number of Participants With Stable Disease and Stable Disease Duration in Expansion Phase|Number of Participants With Objective Response Rate (ORR) in Escalation Phase|Number of Participants With ORR in Expansion Phase|Duration of Response for the Only Participant Shown Partial Response in Expansion Phase|Progression Free Survival (PFS) in Escalation Phase|Progression Free Survival (PFS) in Expansion Phase|Expression Analysis of Tumor Biomarkers (HGF, EGFR, and c-Met ) at Baseline Using Immunohistochemistry (IHC) Method|Expression Analysis of Tumor Biomarkers (EGFR, and c-Met) at Baseline Using Fluorescent in Situ Hybridization (FISH) Method|Number of Participants With c-Met, HER2, EGFR Amplification and ALK Rearrangement at Baseline Using FISH Method|Plasma Concentration of sMet by Study Visits|Number of Participants With EGFR Mutation at Baseline|Number of Participants With KRAS Mutation (GLY12CYS) at Baseline|Number of Participants With PIK3CA Mutation at Baseline|Number of Participants With ROS1 Gene Translocation at Baseline|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Concentration (AUClast)|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Area Under the Plasma Concentration-time Curve 10 (AUC10)|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Maximum Plasma Concentration (Cmax)|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase - Time of Last Quantifiable Concentration (Tlast)|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Escalation Phase -Time to Maximum Plasma Concentration (Tmax)|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUClast|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - AUC24|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Cmax|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tlast|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Escalation Phase - Tmax|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUClast|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - AUC10|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmin|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Cmax|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tlast|Plasma Crizotinib and PF-06260182 Pharmacokinetic Parameter in Expansion Cohort 1 With or Without Co-administration of Dacomitinib - Tmax|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUClast|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - AUC24|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmin|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Cmax|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tlast|Plasma Dacomitinib and PF-05199265 Pharmacokinetic Parameter in Expansion Cohort 2 With or Without Co-administration of Dacomitinib - Tmax",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8081006,10-Aug,14-Feb,14-Feb,12-May-10,30-Mar-15,28-Oct-15,"Clinical Trials Office University of Colorado Hospital (CTO), Aurora, Colorado, United States|DRUG SHIPMENT: University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|CCR, National Cancer Institute, Bethesda, Maryland, United States|Drug Shipment Only, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Drug Shipment Only, Boston, Massachusetts, United States|Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology, East Melbourne, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01121575,2,pf-02341066,pf-00299804,1,1,FALSE,FALSE,FALSE,FALSE,crizotinib,dacomitinib,1,1,TRUE,
166,648,649,NCT00749567,Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer,,Terminated,No Results Available,Non-small-cell Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,Overall response rate|Progression Free Survival|Overall Survival|Quality of life assessment|Toxicity profile,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years and older   (Adult, Older Adult)",Phase 2,13,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/08.15,8-Jul,10-Sep,10-Sep,9-Sep-08,,28-Sep-15,"University Hospital of Heraklion, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO"" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|Sotiria"" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|""Metaxa's"" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00749567,2,erlotinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,bevacizumab,1,1,TRUE,
172,678,679,NCT00383331,Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer,,Terminated,Has Results,Non-Small-Cell Lung Cancer,Drug: Pemetrexed|Drug: Gemcitabine,Best Overall Tumor Response|Progression Free Survival|Time to Progressive Disease|Duration of Response|Time to Treatment Failure|Overall Survival,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,19,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9431|H3E-US-S061,7-Feb,8-Jan,8-Jan,3-Oct-06,14-May-09,3-Jun-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00383331,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
173,683,684,NCT01362296,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,,Completed,Has Results,"Lung Cancer, Non-Small Cell",Drug: GSK1120212|Drug: docetaxel,Progression-Free Survival (PFS) as Assessed by the Investigator (INV)|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Randomized Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Crossover Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Randomized Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Crossover Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Randomized Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Crossover Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Randomized Phase|Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Crossover Phase|Number of Participants With Any Serious Adverse Event (SAE) or Non-serious Adverse Event (AE): Randomized Phase|Number of Participants With Any SAE or Non-serious AE: Crossover Phase|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Randomized Phase|Change From Baseline in SBP and DBP: Crossover Phase|Change From Baseline in Heart Rate: Randomized Phase|Change From Baseline in Heart Rate: Crossover Phase|Number of Participants With a Best Response of Either a Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator: Randomized Phase|Number of Participants With a Best Response of Either a CR or PR as Assessed by the Investigator: Crossover Phase|Duration of Response (DOR) as Assessed by the Investigator: Randomized Phase|Overall Survival (OS)|GSK1120212 Plasma Pharmacokinetic (PK) Concentration,GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,134,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,114653,11-Sep,12-Sep,13-Sep,30-May-11,26-May-14,11-Jul-14,"GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Athens, Georgia, United States|GSK Investigational Site, Coeur d'Alene, Idaho, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, St Louis, Missouri, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Marseille cedex 20, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Paris Cedex 20, France|GSK Investigational Site, Paris cedex 5, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Neo Faliro, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT01362296,2,gsk1120212,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,trametinib,docetaxel,1,1,TRUE,
174,694,695,NCT00190710,A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Gemcitabine|Drug: Carboplatin,To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.|To determine and compare the 1-year survival produced by combined Paraplatin (carboplatin) + Gemcitabine versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2|To determine the safety of combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2|To compare the response rate between treatment groups|To compare the changes in QOL between treatment groups,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 3,242,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9297|B9E-US-S358,4-Mar,,7-Aug,19-Sep-05,,14-Nov-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00190710,2,gemcitabine,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,gemcitabine,carboplatin,1,1,TRUE,
176,698,699,NCT00874419,Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation,ML20981,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: erlotinib|Drug: gemcitabine/carboplatin,Progression free survival|OS|ORR|Time to Progression|lung cancer symptoms and health-related quality of life (HRQoL)|explore the biological markers (tumor tissue),Tongji University|Sun Yat-sen University|Shanghai Chest Hospital|RenJi Hospital|Guangdong Provincial People's Hospital|Peking Union Medical College Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,165,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML20981,8-Aug,10-Jul,12-Jul,2-Apr-09,,25-Sep-14,"Medical Department, Shanghai Pulmonary Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00874419,2,erlotinib,gemcitabine/carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gemcitabine/carboplatin,1,1,TRUE,
182,730,731,NCT01905657,Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010),,"Active, not recruiting",Has Results,Non Small Cell Lung Cancer (NSCLC),Biological: Pembrolizumab|Drug: Docetaxel,Overall Survival (OS)|Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Percentage of Participants Experiencing Adverse Events (AEs)|Percentage of Participants Discontinuing Study Drug Due to AEs|Overall Response Rate (ORR) by RECIST 1.1|Duration of Response (DOR) by RECIST 1.1,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1061,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3475-010|2012-004391-19|132355|MK-3475-010,9-Aug-13,30-Sep-15,30-Mar-20,23-Jul-13,18-Jan-17,15-Feb-19,,,https://ClinicalTrials.gov/show/NCT01905657,2,pembrolizumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,docetaxel,1,1,TRUE,
184,732,733,NCT02831491,A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,,Withdrawn,No Results Available,Stage IV Non-small Cell Lung Cancer,Drug: Ramucirumab|Drug: Docetaxel,Percentage of Participants with Grade ≥3 Neutropenia|Rate of Febrile Neutropenia|Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response|Progression Free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16404|I4T-MC-JVDN|2016-001317-25,16-Nov,17-Jul,18-Jan,13-Jul-16,,13-Dec-16,,,https://ClinicalTrials.gov/show/NCT02831491,2,ramucirumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,ramucirumab,docetaxel,1,1,TRUE,
196,778,779,NCT02633189,Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer,BEVERLY,Unknown status,No Results Available,Non-squamous Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,"progression free survival|overall survival|changes in quality of life scores from baseline|number of patients with complete and partial responses , investigator assessed|number of patients with complete and partial responses , centrally reviewed|worst grade toxicity per patient|progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)","National Cancer Institute, Naples",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BEVERLY|2015-002235-17,16-Apr,17-Dec,18-Jul,17-Dec-15,,17-Jul-17,"Ospedale Ramazzini, Day Hospital Oncologico, Carpi, MO, Italy|Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico, Palermo, PA, Italy|Ospedale di Prato, Prato, PO, Italy|Ospedale S. Chiara, Trento, TN, Italy|Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica, Vicenza, VI, Italy|A.S.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|A.O. S. Giuseppe Moscati, Avellino, Italy|Centro Riferimento Oncologico, Aviano, Italy|AO G. Rummo, Benevento, Italy|Ospedale Senatore Antonio Perrino, Brindisi, Italy|Ospedale A. cardarelli, Campobasso, Italy|U.L.S.S. 15 Veneto, Camposampiero, Italy|A.O. Garibaldi Nesima, Catania, Italy|Centro Clinico Diagnostico G.B. Morgagni, Catania, Italy|Policlinico vittorio Emanuele, Catania, Italy|Ospedale Civile per gli Infermi, Faenza, Italy|Ospedale S. Croce, Fano, Italy|A.O.U. Arcispedale Sant'Anna, Ferrara, Italy|Ospedale Villa Scassi, Genova, Italy|Ospedale di Guastalia, Guastalia, Italy|A.O. Vito Fazzi, Lecce, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Milano, Italy|Ospedale San Paolo, Milano, Italy|A.O. U.L.S.S. 13, Mirano, Italy|A.O.U. Policlinico Modena, Modena, Italy|Azienda Ospedaliera Cardarelli, Napoli, Italy|A.O.U. Seconda Università di Napoli, Napoli, Italy|AORN Ospedale dei Colli - Osp Monaldi, Napoli, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy|Istituto Sacro Cuore Don Calabria, Negrar, Italy|A.O.U. Maggiore della Carità, Novara, Italy|Istituto Oncologico Veneto, Padova, Italy|Policlinico Giaccone, Palermo, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Osp. S. Maria della Misericordia, Perugia, Italy|A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy|Ospedale Guglielmo da Saliceto, Piacenza, Italy|A.O. San Carlo, Potenza, Italy|Ospedale Santa Maria delle Croci - AUSL, Ravenna, Italy|Ospedale Umberto I, Ravenna, Italy|Ospedale degli Infermi Rimini - Ospedale Cervesi Cattolica, Rimini, Italy|IRCCS Centro di Riferimento Oncologico Basilicata, Rionero in Vulture, Italy|Istituto Regina Elena, Roma, Italy|Ospedale Camillo Forlanini, Roma, Italy|Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Universitario Campus Bio Medico, Roma, Italy|Ospedale di Sondrio, Sondrio, Italy|Ospedale Fabrizio Spaziani di Frosinone, Sora, Italy|Ospedale Maggiore, Trieste, Italy|Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine, Udine, Italy|Ospedale S. Andrea, Vercelli, Italy|A.O.U. Integrata, Verona, Italy|ASL Viterbo - Ospedale Belcolle, Viterbo, Italy",,https://ClinicalTrials.gov/show/NCT02633189,2,erlotinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,bevacizumab,1,1,TRUE,
209,812,813,NCT04099836,Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib,,Not yet recruiting,No Results Available,Non Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Bevacizumab,Objective response rate (ORR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors RECIST 1.1 (brand name)|Progression free survival as measured by Response Evaluation Criteria In Solid Tumors RECIST 1.1 (brand name) as assessed by the investigator.|Overall survival as noted by follow-up via composite of telephone or medical record review.|AEs as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,39,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00103723,30-Oct-19,30-Oct-22,30-Oct-24,23-Sep-19,,23-Sep-19,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT04099836,2,atezolizumab,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,atezolizumab,bevacizumab,1,1,TRUE,
210,819,820,NCT00701558,A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer,,Completed,Has Results,Non-small Cell Lung Cancer Metastatic,Drug: Erlotinib|Drug: Gemcitabine,Time to Disease Progression|Overall Response Rate (ORR)|Overall Survival,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML20951|2007-002135-83,8-Aug,10-Oct,10-Dec,19-Jun-08,19-May-16,24-Jun-16,"Bucuresti, Romania",,https://ClinicalTrials.gov/show/NCT00701558,2,erlotinib,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gemcitabine,1,1,TRUE,
211,825,826,NCT01642004,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017),,"Active, not recruiting",Has Results,Squamous Cell Non-small Cell Lung Cancer,Biological: Nivolumab|Drug: Docetaxel,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) at Primary Endpoint|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,352,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-017|2011-004792-36,26-Sep-12,17-Nov-14,23-Jan-20,17-Jul-12,17-Mar-16,9-Aug-19,"Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autónoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Viña Del Mar, Valparaiso, Chile|Local Institution, Antofagasta, Chile|Local Institution, Santiago, Chile|Local Institution, Praha 8, Czechia|Local Institution, Avignon Cedes 9, France|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Essen, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Krefeld, Germany|Local Institution, Budapest, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin 9, Dublin, Ireland|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barakaldo, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Cottingham, EAST Yorkshire, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01642004,2,nivolumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,nivolumab,docetaxel,1,1,TRUE,
212,826,827,NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,OAK,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Docetaxel,"Percentage of Participants Who Died: PP-ITT|Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP|Overall Survival (OS): PP-ITT|OS: TC1/2/3 or IC1/2/3 Subgroup of PP|Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT|Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP|Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT|PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP|Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT|Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP|Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT|DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab|Maximum Observed Serum Atezolizumab Concentration (Cmax)|Minimum Observed Serum Atezolizumab Concentration (Cmin)|Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)|EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items|EORTC QLQ-C30 Questionnaire Score: Functional Subscales|EORTC QLQ-C30 Questionnaire Score: GHS Scale|EORTC QLQ-C30 Questionnaire Score: Symptom Subscale|EORTC QLQ-LC13 Questionnaire Score: Alopecia|EORTC QLQ-LC13 Questionnaire Score: Coughing|EORTC QLQ-LC13 Questionnaire Score: Dysphagia|EORTC QLQ-LC13 Questionnaire Score: Dyspnea|EORTC QLQ-LC13 Questionnaire Score: Hemoptysis|EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder|EORTC QLQ-LC13 Questionnaire Score: Pain in Chest|EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy|EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts|EORTC QLQ-LC13 Questionnaire Score: Sore Mouth",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1225,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO28915|2013-003331-30,11-Mar-14,7-Jul-16,9-Jan-19,11-Dec-13,2-Jul-17,8-Feb-19,"Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States|Roy & Patricia Disney Family Cancer Center, Burbank, California, United States|St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States|Kaiser Permanente - Hayward, Hayward, California, United States|Scripps Clinic; Hematology & Oncology, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Univ of Calif, Los Angeles; Hematology/Oncology, Los Angeles, California, United States|North Valley Hem Onc Med Grp; Thomas&Dorothy Leavey Can Ctr, Northridge, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|TMPN/ Cancer Care Associates, Redondo Beach, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|K. Permanente - S. San Fran, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Kaiser Permanente - Franklin; Kaiser Permanente - Lone Tree, Lone Tree, Colorado, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Orlando Health Inc., Orlando, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Hematology-Oncology; Associates of the Quad Cities, Bettendorf, Iowa, United States|New England Cancer Specialists, Scarborough, Maine, United States|Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building, Detroit, Michigan, United States|US Oncology Research at Minnesota Oncology, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Billings Clinic; Research Center, Billings, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Oncology Hematology West Midwest, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States|Summit Medical Center, Florham Park, New Jersey, United States|Luckow Pavillion, Valley Hosp; Office of Clinical Trials, Paramus, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Roswell Park Cancer Inst., Buffalo, New York, United States|New York Oncology Hematology PC - Latham, Clifton Park, New York, United States|North Shore Hem Onc Associates, East Setauket, New York, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, United States|Cancer Treatment Centers of America-Tulsa, Tulsa, Oklahoma, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|The Methodist Cancer Center, Houston, Texas, United States|Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|St. Mary Medical Center, Walla Walla, Washington, United States|Aurora Health Care; Patient Centered Research, Milwaukee, Wisconsin, United States|Instituto Medico Rio Cuarto, Córdoba, Argentina|COIBA, Provincia De Buenos Aires, Argentina|Instituto de Oncología de Rosario, Rosario, Argentina|Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin, Innsbruck, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Lkh Vöcklabruck; I. Abt. Für Innere Medizin, Vöcklabruck, Austria|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|ONCOCENTRO APYS; Oncología, Vina Del Mar, Chile|Helsinki University Central Hospital; Dep. of Pulmonary Medicine, Helsinki, Finland|Oulu University Hospital; Oncology, Oulu, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Institut Sainte Catherine, Avignon, France|Hopital Jean Minjoz; Pneumologie, Besancon, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Centre Francois Baclesse, Caen, France|Hopital Gabriel Montpied; Service de Pneumologie, Clermont-ferrand, France|Centre Hospitalier Intercommunal; Service de Pneumologie, Creteil, France|Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie, Grenoble, France|Centre Jean Bernard; Radiotherapie Chimiotherapie, Le Mans, France|Centre Oscar Lambret, Lille, France|Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique, Marseille, France|Hopital Emile Muller;Pneumologie, Mulhouse, France|Hopital Cochin; Unite Fonctionnelle D Oncologie, Paris, France|Hopital Saint Louis; Oncologie Medicale, Paris, France|GH Paris Saint Joseph; Pneumologie, Paris, France|Hopital Tenon;Pneumologie, Paris, France|Centre Hospitalier Lyon Sud; Pneumologie, Pierre Benite, France|CH de la region d Annecy, Pringy, France|Hopital de Pontchaillou; Service de Pneumologie, Rennes, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Hopital Foch; Pneumologie, Suresnes, France|Hia Sainte Anne; Pneumologie, Toulon, France|Hopital Larrey; Pneumologie, Toulouse, France|Helios Klinikum Emil von Behring GmbH, Berlin, Germany|Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie, Frankfurt, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Krankenhaus Merheim Lungenklinik, Köln, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Germany|Uoa Sotiria Hospital; Oncology, Athens, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Thermi Clinic; Oncology Clinic, Thermi Thessalonikis, Greece|Grupo Angeles, Guatemala City, Guatemala|Semmelweis Egyetem X; Pulmonologiai Klinika, Budapest, Hungary|University of Pecs, I st Dept of Internal Medicine, Pecs, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania, Italy|Seconda Universita' Degli Studi; Divsione Di Oncologia Medica, Napoli, Campania, Italy|Azienda Ospedaliera Univ Parma; Dept Oncologia Medica, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliero-Uni Ria Di Udine; Dept. Di Oncologia - Padiglione Pennato, Udine, Friuli-Venezia Giulia, Italy|Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna, Roma, Lazio, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, Liguria, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|POLICLINICO RODOLICO, U.O. di Oncologia Medica, Catania, Sicilia, Italy|Ospedale San Luca; Oncologia, Lucca, Toscana, Italy|A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii, Pisa, Toscana, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina, Verona, Veneto, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, Japan|National Cancer Center Hospital East; Thoracic Oncology, Chiba, Japan|National Hospital Organization Shikoku Cancer Center; Internal Medicine, Ehime, Japan|National Hospital Organization Kyushu Cancer Center, Thoracic Oncology, Fukuoka, Japan|Kobe City Medical Center General Hospital; Respiratory Medicine, Hyogo, Japan|Hyogo Cancer Center; Thoracic Oncology, Hyogo, Japan|Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan|Okayama University Hospital; Respiratory and Allergy Medicine, Okayama, Japan|Kindai University Hospital; Medical Oncology, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center; Internal Medicine, Osaka, Japan|Saitama Cancer Center; Thoracic Oncology, Saitama, Japan|Shizuoka Cancer Center; Thoracic Oncology, Shizuoka, Japan|National Cancer Center Hospital; Thoracic Medical Oncology, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Respiratory Medicine, Tokyo, Japan|Tokyo Medical University Hospital; Dept of Surgery, Tokyo, Japan|National Hospital Organization, Yamaguchi - Ube Medical Center; Oncology Medicine, Yamaguchi, Japan|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital; Hematology Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National Uni Hospital; Internal Medicine, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of|Seoul St.Mary's Hospital; Medical Oncology, Seoul, Korea, Republic of|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, Netherlands|Catharina Ziekenhuis; Dept of Lung Diseases, Eindhoven, Netherlands|Antonius Ziekenhuis; Dept of Lung Diseases, Nieuwegein, Netherlands|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Waikato Hospital; Dept of Medical Oncology, Hamilton, New Zealand|Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway|Centro Hemato Oncologico Panama, Panama, Panama|Medical University of Gdansk, Gdansk, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Med.-Polonia Sp. z o.o. NSZOZ, Poznan, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, Poland|Hospital Geral; Servico de Pneumologia, Coimbra, Portugal|Hospital Pulido Valente; Servico de Pneumologia, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Medical Radiological Research Centre Rams; Dept. of Radiotherapy & Chemotherapy of Hemoblastosis, Obninsk, Russian Federation|City Clinical Onc., Saint-Petersburg, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Clinic for Pulmonology, Clinical Center of Serbia, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Institute for pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset, Lungmedicinkliniken, Goeteborg, Sweden|Universitetssjukhuset Linköping; Lungmedicinkliniken, Linköping, Sweden|Karolinska Universitetssjukhuset, Solna; Lung Allergikliniken N10:02, Stockholm, Sweden|Kantonsspital Baden; Medizinische Klinik, Onkologie, Baden, Switzerland|HUG; Oncologie, Geneve, Switzerland|Luzerner Kantonsspital; Medizinische Onkologie, Luzern, Switzerland|China Medical University Hospital, Taichung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Ankara University Medical Faculty; Medikal Onkoloji, Ankara, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|Izmir Suat Seren Chest Diseases and Surgery Research Hospital, Izmir, Turkey|State Medical Academy; Oncology, Dnipropetrovsk, Ukraine|Karkiv Regional Oncology Center, Kharkiv, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Uzhgorod Nat. University Central Municip Hosp; Onc Center, Uzhgorod, Ukraine|Diana Princess of Wales Hosp., Grimsby, United Kingdom|University College London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Kings Mill Hospital, Sutton in Ashfield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02008227,2,atezolizumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,atezolizumab,docetaxel,1,1,TRUE,
218,852,853,NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,,"Active, not recruiting",Has Results,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug: PF-06463922|Drug: Crizotinib,"Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1|Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)|Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)|Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)|Duration of Response (DOR) and Intracranial DOR (Phase 1)|Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 1)|Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)|Progression-Free Survival (PFS) (Phase 1)|Overall Survival (OS) (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)|Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)|Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)|Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)|Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)|Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Renal Clearance (CLr) of PF-06463922 (Phase 1)|Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)|Time for Cmax (Tmax) of Midazolam (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)|Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)|Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)|Terminal Half-Life of Midazolam (Phase 1)|Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)|Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)|Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)|Time to Tumor Response (TTR) and Intracranial TTR (Phase 2)|Duration of Response (DOR) and Intracranial DOR (Phase 2)|Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 2)|Time to Progression (TTP) on the Last Prior Therapy (Phase 2)|Time to Tumor Progression （TTP) and Intracranial TTP (Phase 2)|Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)|Progression-Free Survival (PFS) (Phase 2)|Overall Survival (Phase 2)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)|Time for Cmax (Tmax) of PF-06463922 (Phase 2)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)|Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)|Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)|Terminal Half-Life of PF-06463922 (Phase 2)|Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)|Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)|Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)|Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2)|Number of Participants With Treatment-Emergent Adverse Events (Phase 1 and Phase 2)|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Hematology|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Chemistry|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Coagulation, Lipids and Urinalysis|Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1 and Phase 2)|Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1 and Phase 2)|Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1 and Phase 2)|Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)|Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)|Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 2,334,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,B7461001|2013-002620-17,8-Jan-14,15-Mar-17,19-Aug-20,28-Oct-13,28-May-18,25-Oct-19,"Highlands Oncology Group/Research, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|MDZ: Yale-New Haven Hospital, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Center Institute, Detroit, Michigan, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Rockefeller Patient Pavilion - Memorial Sloan Kettering, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester Regional Health System, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute (Pharmacy), Nashville, Tennessee, United States|Chris O'Brien Lifehouse, Sydney Local Health District [rpa], New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|University Hospital Antwerp, Edegem, Belgium|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU Grenoble/ Hôpital Albert Michallon, Grenoble Cedex 9, France|CHU Grenoble/Hopital Albert Michallon, Grenoble Cedex 9, France|CHU de Rennes - Hôpital Pontchaillou - CIC Inserm, Rennes Cedex 9, France|CHU de Rennes - Hôpital Pontchaillou, Rennes Cedex 9, France|Institut Universitaire du Cancer de Toulouse (IUCT-O), Toulouse Cedex 9, France|Institut Gustave Roussy (comite poumon-pneumologie), Villejuif Cedex, France|Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques, Villejuif, France|Universitaetsklinik Koeln, Cologne, NRW, Germany|Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong|Struttura Operativa Complessa Oncologia, Aviano (PN), Italy|Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milano, Italy|Unita di Farmacologia Clinica e Nuovi Farmaci, Milano, Italy|Oncologia Medica, Perugia, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National University Hospital Medical Centre, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Hospital Universitario Quiron Madrid, Pozuelo de Alarcón, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia, Barcelona, Spain|Hospital of Lausanne (CHUV), Lausanne, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|National Taiwan University Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01970865/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01970865/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01970865,2,pf-06463922,crizotinib,1,1,FALSE,FALSE,FALSE,FALSE,lorlatinib,crizotinib,1,1,TRUE,
220,863,864,NCT00518011,A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.,,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Erlotinib|Drug: Gemcitabine,Progression Free Survival|Objective Response Rate|Disease Control Rate|Duration of Response|Overall Survival|Mean Change in Pulse Rate From Baseline|Mean Change in Blood Pressure From Baseline|Mean Change in Body Temperature From Baseline,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,17,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML20063,7-Aug,9-Feb,9-Feb,17-Aug-07,1-Apr-16,16-May-16,"Auchenflower, Australia|Chermside, Australia|Footscray, Australia|Greenslopes, Australia|Lismore, Australia|Melbourne, Australia|Melbourne, Australia|Parkville, Australia|Randwick, Australia|Richmond, Australia|St. Leonards, Australia|Sydney, Australia|Wodonga, Australia|Wollongong, Australia",,https://ClinicalTrials.gov/show/NCT00518011,2,erlotinib,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gemcitabine,1,1,TRUE,
222,881,882,NCT01204307,Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation,,Completed,No Results Available,Advanced Non-Squamous Non-Small Cell Lung Cancer,Drug: Docetaxel/cisplatin|Drug: Pemetrexed/cisplatin,Response rate to erlotinib with Docetaxel/cisplatin or Pemetrexed/cisplatin|Progression-free survival and overall survival after erlotinib treatment with 1st line Docetaxel/cisplatin or Pemetrexed/cisplatin.,Chang Gung Memorial Hospital|Taiwan Chest Disease Association,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,99-1896C,10-Jan,14-Dec,15-Jun,17-Sep-10,,28-Jul-15,"Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung, Taiwan|Chang Gung Memorial Hospital, Taipei, Taiwan|McKay Memorial Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01204307,2,docetaxel/cisplatin,pemetrexed/cisplatin,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel/cisplatin,pemetrexed/cisplatin,1,1,FALSE,Cisplatin is not an approved drug
238,961,962,NCT02838420,A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC),,"Active, not recruiting",Has Results,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,Drug: Alectinib|Drug: Crizotinib,Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1|PFS as Determined by Independent Review Committee (IRC) Using RECIST v1.1|Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Using RECIST v1.1|Time to Progression of Disease in the CNS as Determined by IRC Using RECIST v1.1|Time to Progression of Disease in the CNS as Determined by IRC Using Response Assessment in Neuro-Oncology (RANO)|Duration of Response (DOR) Assessed by Investigator Using RECIST v1.1|Overall Survival Time|Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events|Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Core (QLQ-C30) Score|Time to Deterioration Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC13) Score|Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite|Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite|Time to Cmax (Tmax) of Alectinib and Its Metabolite,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,187,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YO29449,3-Aug-16,31-May-18,6-Dec-19,20-Jul-16,11-Jul-19,10-Sep-19,"Beijing Cancer Hospital, Beijing, China|Beijing Chest Hospital; Oncology Department, Beijing, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Second Affiliated Hospital of Third Military Medical University, Chongqing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai chest hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Khon Kaen University, Khon Kaen, Thailand|Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory, Songkhla, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02838420/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02838420/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02838420,2,alectinib,crizotinib,1,1,FALSE,FALSE,FALSE,FALSE,alectinib,crizotinib,1,1,TRUE,
244,975,976,NCT03122717,Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,,Recruiting,No Results Available,Non-Small Cell Lung Cancer,Drug: Gefitinib|Drug: Osimertinib,Number of patients completing combination therapy with gefitinib and osimertinib for 6 x 28 day cycles|Rate of treatment-related Grade 3-5 adverse events|Objective response rate|Progression free survival|Overall Survival,Dana-Farber Cancer Institute|AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,64,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-627,9-May-17,20-Apr,23-Apr,21-Apr-17,,18-Oct-19,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT03122717,2,gefitinib,osimertinib,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,osimertinib,1,1,TRUE,
248,993,994,NCT00434174,Safety of Everolimus and Pemetrexed in Lung Cancer Patients,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Everolimus|Drug: Pemetrexed,Establish feasible dose levels/regimens of everolimus combined with pemetrexed chemotherapy through estimation of the End-of-Cycle 1 DLT rate.|Assess the ability to deliver the standard pemetrexed treatment (relative dose intensity) Assess the pharmacokinetics of everolimus and chemotherapy Evaluate the effect of therapy (RECIST),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001C2112|2006-002759-34,6-Dec,10-Dec,10-Dec,13-Feb-07,,19-Dec-12,"Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Koeln, Germany",,https://ClinicalTrials.gov/show/NCT00434174,2,everolimus,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,everolimus,pemetrexed,1,1,TRUE,
263,1118,1119,NCT00005059,Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: paclitaxel,response rate,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,65 Years and older   (Older Adult),Phase 2,51,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N9921|CDR0000067656,Jan-00,3-Jul,6-Apr,26-May-04,,14-Jul-16,"CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|Ann Arbor Hematology Oncology, Ypsilanti, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00005059,2,carboplatin,paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,paclitaxel,1,1,TRUE,
280,1209,1210,NCT00541099,Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Biological: bevacizumab|Drug: docetaxel,Survival|Progression-free Survival|Overall Survival|Response Rate|Toxicity According to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),All,75 Years to 120 Years   (Older Adult),Phase 2,11,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000555019|P30CA022453|WSU-2007-053,8-Jan,13-Jan,13-Jan,8-Oct-07,21-Aug-14,27-Mar-19,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00541099,2,bevacizumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,bevacizumab,docetaxel,1,1,TRUE,
288,1241,1242,NCT00096486,Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Drug: everolimus|Drug: gefitinib,Overall Objective Response,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 1|Phase 2,74,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,04-033|MSKCC-04033,4-May,10-Jul,10-Jul,10-Nov-04,21-Jan-16,21-Jan-16,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00096486,2,everolimus,gefitinib,1,1,FALSE,FALSE,FALSE,FALSE,everolimus,gefitinib,1,1,TRUE,
290,1247,1248,NCT02488694,Maintaining ERBB Blockade in EGFR-mutated Lung Cancer,MARBLE,Terminated,No Results Available,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Drug: Afatinib|Drug: Pemetrexed,"Progression-free survival|Overall survival|Objective response rate|Quality of Life|Safety (intensity and incidence of adverse events, graded according to US NCI CTCAE Version 4.03)",AIO-Studien-gGmbH|Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 2,4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AIO-TRK-0114,15-Nov,17-Dec,17-Dec,2-Jul-15,,9-Jan-18,"Universitätsklinikum Essen, Essen, Germany",,https://ClinicalTrials.gov/show/NCT02488694,2,afatinib,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,pemetrexed,1,1,TRUE,
297,1263,1264,NCT01836575,Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2,PS2,Completed,No Results Available,Non Small Cell Lung Carcinoma,Drug: Pemetrexed|Drug: Carboplatin,Overall survival|Safety evaluation|Progression free survival|Response Rate,"Instituto Nacional de Cancer, Brazil|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 3,228,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H3E-BL-O027-PS2|H3E - US -I023|INCA-Lung001,8-Apr,12-Jan,12-Dec,22-Apr-13,,22-Apr-13,"The Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Instituto do Câncer do Ceará - ICC, Fortaleza, Ceará, Brazil|Hospital Lifecenter, Belo Horizonte, Minas Gerais, Brazil|Hospital Caridade de Ijuí - CACON, Ijuí, RS, Brazil|Hospital São Lucas, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Santa Catarina, Brazil|Hospital Amaral Carvalho, Jaú, São Paulo, Brazil|INCA, Rio de Janeiro, Brazil|Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01836575,2,pemetrexed,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,carboplatin,1,1,TRUE,
302,1284,1285,NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment,,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Erlotinib|Drug: Alectinib,"Recommended Phase 2 Dose (RP2D) of Alectinib|Percentage of Participants With Dose Limiting Toxicities (DLTs)|Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Naive Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in RE Population|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Pretreated Participants|Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Naive Participants|Duration of Response (DoR) as Assessed by IRC in RE Population|Percentage of Participants With PD as Assessed by IRC According to RECIST v1.1 or Death From Any Cause in Safety Population|Progression Free Survival (PFS) as Assessed by IRC in Safety Population|Percentage of Participants Who Died of Any Cause|Overall Survival (OS)|Percentage of Participants Achieving CR, PR or Stable Disease (SD) According to RECIST v1.1 in RE Population|Percentage of Participants Achieving Central Nervous System (CNS) Objective Response as Assessed by IRC According to RECIST v1.1|Percentage of Participants Achieving CNS Objective Response as Assessed by IRC According to Radiology Assessment in Neuro-Oncology (RANO) Criteria|CNS Duration of Response (CDoR) as Assessed by IRC According to RECIST v1.1|CDoR as Assessed by IRC According to RANO Criteria|Percentage of Participants With CNS Progression as Assessed by IRC According to RECIST v 1.1|Maximum Observed Plasma Concentration (Cmax) of Alectinib|Time to Cmax (Tmax) of Alectinib|Time to Last Measurable Plasma Concentration (Tlast) of Alectinib|Area Under the Plasma Concentration-Time Curve From Time 0 to 10 Hours Post-dose (AUC[0-10]) of Alectinib|Area Under the Plasma Concentration-Time Curve From Time 0 to Tlast (AUC[0-last]) of Alectinib|Cmax of Alectinib Metabolite|Tmax of Alectinib Metabolite|Tlast of Alectinib Metabolite|AUC(0-10) of Alectinib Metabolite|AUC(0-last) of Alectinib Metabolite|Metabolite to Parent Ratio Based on AUC(0-10)|Metabolite to Parent Ratio Based on AUC(0-last)|Trough Plasma Concentration (Ctrough) of Alectinib|Ctrough of Alectinib Metabolite|Peak to Trough Ratio of Alectinib|Accumulation Ratio of Alectinib|Accumulation Ratio of Alectinib Metabolite",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,138,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NP28673|2012-004455-36,20-Jun-13,24-Oct-14,27-Oct-17,28-Feb-13,26-May-16,2-Nov-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|UC Irvine Medical Center, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|UCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Hospital Cancer Inst, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Midwestern Regional Medical Center; Office of Research, Zion, Illinois, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Columbia University Medical Center; Department of Hematology/Oncology, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Texas Oncology, P.A., Dallas, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Townsville General Hospital, Douglas, Queensland, Australia|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|University Hospital Herlev, Herlev, Denmark|CHU Angers - Hôpital Hôtel Dieu, Angers, France|Hopital Morvan, Brest, France|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|CHU de Grenoble - Hôpital Nord; Service d'Oncologie Thoracique, Grenoble, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hôpital Nord - AP-HM Marseille#; Gastroenterology and Hepatology, Marseille cedex 20, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|ICO Rene Gauducheau; CEC, St Herblain, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Larrey, Toulouse, France|Charité Campus Virchow-Klinikum; Department of Cardiology, Berlin, Germany|Diakonie Kaiserswerth; Florence-Nightingale-Krankenhaus, Düsseldorf, Germany|LungenClinic Großhansdorf, Großhansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikum Koeln-Merheim, Koeln, Germany|Mathias-Spital Rheine, Rheine, Germany|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, Italy|AO San Camillo Forlanini, Roma, Lazio, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale Versilia, Lido Di Camaiore, Toscana, Italy|Presidio Ospedaliero Campo di Marte, Lucca, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Umbria, Italy|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Maastricht University Medical Centre; Afdeling Klinische Farmacie en Toxicologie, Maastricht, Netherlands|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin""; Chemotherapy Departement, Moskva, Moskovskaja Oblast, Russian Federation|National University Hospital; Investigational Medicine Unit, Singapore, Singapore|Johns Hopkins Singapore, Singapore, Singapore|Hospital General Univ. de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hosp Clinico Univ Lozano Blesa, Zaragoza, Spain|Karolinska, Stockholm, Sweden|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Marsden Hospital;Dept of Haematology Oncology Research, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01801111,2,erlotinib,alectinib,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,alectinib,1,1,TRUE,
323,1403,1404,NCT02967133,A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer,,"Active, not recruiting",No Results Available,"Non-Small-Cell Lung Cancer Metastatic|Non-Small Cell Carcinoma of Lung, TNM Stage 4|Nonsmall Cell Lung Cancer|Non Small Cell Lung Cancer Recurrent",Drug: Nivolumab|Drug: nab-paclitaxel,Progression-Free Survival,"Alliance Foundation Trials, LLC.|Celgene Corporation|Bristol-Myers Squibb",All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFT-31,16-Dec,20-Dec,20-Dec,18-Nov-16,,30-Jul-19,"St. Elizabeth's Healthcare, Edgewood, Kentucky, United States|Metro Minnesota community oncology research consortium, Saint Louis Park, Minnesota, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT02967133,2,nivolumab,nab-paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,nivolumab,nab-paclitaxel,1,1,TRUE,
326,1423,1424,NCT00456833,Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: RAD001|Drug: erlotinib,"Phase 1: Dose limiting toxicities (DLT) and PK drug-drug interaction (DDI) measured during first 28 days of combined treatment for each treatment regimen and dose.|Phase 2: Tumor response assessed by CT scans measured at baseline and after 8 weeks of treatment for each feasible dose/regimen determined in phase 1|Phase 1: Tumor response assessed by CT scans measured at baseline, monthly until month 4 then q2months until progression|Phase 2: Safety and steady state drug levels evaluated monthly|Phase 1 and 2: Exploratory Biomarker assessment from archival tumor tissue",Novartis Pharmaceuticals|Novartis,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,248,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001C2111|2004-003017-16,5-Jun,11-Mar,,5-Apr-07,,13-Apr-12,"Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Richmond, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT00456833,2,rad001,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,afinitor,erlotinib,1,1,TRUE,
327,1426,1427,NCT01407822,Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer,EMERGING,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: Gemcitabine/cisplatin,The objective response rate (ORR) in neoadjuvant treatment|Complete resection rate|Pathological complete response (pCR) rate|Progression free survival（PFS）|3 year overall survival (OS) rate|Number of Participants with Adverse Events|Quality of Life (QOL),Guangdong Association of Clinical Trials|Guangdong Provincial People's Hospital|Tianjin Medical University Cancer Institute and Hospital|Jilin Provincial Tumor Hospital|Jiangsu Cancer Institute & Hospital|Zhejiang Cancer Hospital|Beijing Cancer Hospital|Sun Yat-sen University|West China Hospital|The First Affiliated Hospital of Dalian Medical University|Peking University People's Hospital|Health Science Center of Xi’an Jiaotong University|Shanghai Zhongshan Hospital|Guangzhou General Hospital of Guangzhou Military Command|The First Affiliated Hospital of Guangzhou Medical University|Fujian Medical University Union Hospital|Linyi Tumour Hospital|Northern Jiangsu Province People's Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTONG 1103|ML25304,5-Dec-11,24-Apr-18,22-Dec,2-Aug-11,,11-Sep-18,"Guangdong General Hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01407822,2,erlotinib,gemcitabine/cisplatin,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gemcitabine/cisplatin,1,1,FALSE,Cisplatin is not an approved drug
365,1590,1591,NCT02672358,Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC,,Withdrawn,No Results Available,Non-Small-Cell Lung Cancer,Drug: Dabrafenib|Drug: Trametinib,Overall Response Rate (ORR) by investigator assessment|Duration of response (DOR)|Disease control rate (DCR)|Progression-free survival (PFS)|Overall survival (OS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDRB436E1201,3-Sep-18,2-Sep-19,7-Dec-20,3-Feb-16,,10-Aug-18,,,https://ClinicalTrials.gov/show/NCT02672358,2,dabrafenib,trametinib,1,1,FALSE,FALSE,FALSE,FALSE,dabrafenib,trametinib,1,1,TRUE,
366,1593,1594,NCT00051493,ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.,,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: ALIMTA|Drug: Carboplatin,,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6142|H3E-MC-JMEZ,2-Apr,,2-Dec,14-Jan-03,,19-Jul-06,"Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00051493,2,alimta,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,alimta,carboplatin,1,1,TRUE,
367,1594,1595,NCT01004601,Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: docetaxel|Drug: pemetrexed,Objective response rate|PFS-progression free survival|OS-overall survival,Chang Gung Memorial Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,179,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,98-2587B,5-Mar,8-Oct,8-Oct,30-Oct-09,,30-Oct-09,"Chang Gung Memorial Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01004601,2,docetaxel,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,pemetrexed,1,1,TRUE,
373,1621,1622,NCT00684099,Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Docetaxel|Drug: Pemetrexed,Evaluation of Dose Limited Toxicity and Maximum Tolerated Dose for the docetaxel/pemetrexed doublet|Response rate for the docetaxel/pemetrexed doublet,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/05.18,6-May,9-May,9-May,26-May-08,,15-Dec-09,"University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""IASO"" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|Sotiria"" General Hospital, 1st Dep of Pulmonary Diseases, Athens, Greece|""Diabalkaniko"" Hospital of Thessaloniki, Thessaloniki, Greece|""Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00684099,2,docetaxel,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,pemetrexed,1,1,TRUE,
378,1657,1658,NCT00621049,"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC",,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Drug: Docetaxel/Carboplatin,Disease-free Survival|Safety|2-year Survival|Overall Survival (OS),"SCRI Development Innovations, LLC|Genentech, Inc.|Sanofi",All,"18 Years and older   (Adult, Older Adult)",Phase 2,112,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LUN 142|US_IST_12218|AVF3923s,7-Dec,13-Jul,14-Feb,22-Feb-08,14-May-15,8-Jun-15,"Northeast Alabama Medical Center, Anniston, Alabama, United States|Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Gulfcoast Oncology Associates, St. Petersburg, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Providence Medical Group, Terre Haute, Indiana, United States|RHHP/Hope Cancer Center, Terre Haute, Indiana, United States|Baptist Hospital East, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Hematology Oncology Life Center, Alexandria, Louisiana, United States|Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Cancer Care of Western North Carolina, Asheville, North Carolina, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Associates in Hematology Oncology, Chattanooga, Tennessee, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00621049,2,docetaxel/carboplatin/bevacizumab/erlotinib,docetaxel/carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel/carboplatin/bevacizumab/erlotinib,docetaxel/carboplatin,1,1,TRUE,
381,1672,1673,NCT01405079,Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation,ADJUVANT,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer,Drug: Gefitinib|Drug: Vinorelbine+Cisplatin,"Disease free survival|Overall survival|3 yeas DFS rate, 5 years DFS rate, 5 years OS rate|Number of Participants with Adverse Events|Quality of life","Guangdong Association of Clinical Trials|Guangdong Provincial People's Hospital|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Jilin Provincial Tumor Hospital|Liaoning Tumor Hospital & Institute|First Hospital of China Medical University|Chinese PLA General Hospital|Peking Union Medical College Hospital|Peking University People's Hospital|Beijing Chest Hospital|309th Hospital of Chinese People's Liberation Army|Beijing Cancer Hospital|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|Qingdao University|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Soochow University|Fudan University|Shanghai Pulmonary Hospital, Shanghai, China|Zhejiang Cancer Hospital|Zhejiang University|Wuhan Union Hospital, China|Tongji Hospital|West China Hospital|Tang-Du Hospital",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,222,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTONG 1104,11-Jul,17-Mar,20-Dec,29-Jul-11,,6-Jun-17,"Guangdong General Hospital, Guangzhou, China",,https://ClinicalTrials.gov/show/NCT01405079,2,gefitinib,vinorelbine+cisplatin,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,vinorelbine+cisplatin,1,1,FALSE,Cisplatin is not an approved drug
387,1711,1712,NCT03256721,Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC,,Unknown status,No Results Available,Nonsmall Cell Lung Cancer,Drug: Apatinib/docetaxel/pemetrexed|Drug: docetaxel/pemetrexed,progression-free survival,Fuzhou General Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,135,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SECGOLC003,16-Aug-17,26-Aug-18,26-May-19,22-Aug-17,,22-Aug-17,"Fuzhou general hospital, Fuzhou, Fujian, China",,https://ClinicalTrials.gov/show/NCT03256721,2,apatinib/docetaxel/pemetrexed,docetaxel/pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,apatinib/docetaxel/pemetrexed,docetaxel/pemetrexed,1,1,FALSE,Apatinib is not an approved drug
401,1753,1754,NCT03616691,Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC,,Not yet recruiting,No Results Available,Non Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Bevacizumab,The primary objective for this study is to evaluate efficacy of atezolizumab with bevacizumab after radiologically progress of atezolizumab monotherapy|Best overall response rate|Progression-free survival|Duration of response|Overall survival|Adverse events (AEs),Samsung Medical Center,All,"20 Years and older   (Adult, Older Adult)",Phase 2,46,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018-05-170,1-Aug-18,30-Jun-20,30-Jun-20,6-Aug-18,,6-Aug-18,,,https://ClinicalTrials.gov/show/NCT03616691,2,atezolizumab,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,atezolizumab,bevacizumab,1,1,TRUE,
412,1802,1803,NCT02405910,Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.,,Withdrawn,No Results Available,Non-small Cell Lung Cancer,Drug: Nab-paclitaxel|Drug: Gemcitabine,Progression Free Survival|To explore differences in progression free survival (PFS) between two dose combinations of nab-paclitaxel with Gemcitabine in patients with advanced NSCLC.,West Virginia University|Celgene Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WVU020514,15-Mar-15,17-Dec,23-Apr,1-Apr-15,,6-Nov-17,"West Virginia University Hospitals - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT02405910,2,nab-paclitaxel,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,nab-paclitaxel,gemcitabine,1,1,TRUE,
416,1814,1815,NCT02422381,MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: MK-3475|Drug: Gemcitabine,Frequency of Toxicities (determine any changes in signs or symptoms that may represent drug toxicity)|Progression Free Survival|Overall Survival|Disease Response,"Providence Health & Services|Merck Sharp & Dohme Corp.|Providence Cancer Center, Earle A. Chiles Research Institute",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,16,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-011A,20-Jul-15,20-Aug,21-Apr,21-Apr-15,,28-Oct-19,"Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States|Providence Oncology & Hematology Care Clinic - Westside, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02422381,2,mk-3475,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,gemcitabine,1,1,TRUE,
422,1851,1852,NCT03896074,Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT),BEAT,Not yet recruiting,No Results Available,Non-small-cell Lung Cancer Patients,Drug: Atezolizumab|Drug: Bevacizumab,Overall Survival (OS)|Response rate (complete + partial responses)|Progression-free survival|Overall survival according to presence of bone and/ or hepatic metastases,Fondazione Ricerca Traslazionale,All,"18 Years and older   (Adult, Older Adult)",Phase 2,206,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FoRT 05- BEAT,19-May,22-May,23-Apr,29-Mar-19,,29-Mar-19,"AOU Ospedali Riuniti ""Umberto I- G.M.Lancisi-G.Salesi"", Ancona, Italy|IRCCS Oncologico Istituto Tumori ""Giovanni Paolo II"", Bari, Italy|P.O. Antonio Perrino, Brindisi, Italy|A.O. Per l' emergenza Cannizzaro, Catania, Italy|Irccs S.R.L. Irst, Meldola, Italy|AO Papardo, Messina, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Istituto Nazionale Tumori di Napoli IRCCS Pascale, Napoli, Italy|Ospedale Sacro Cuore- Don Calabria, Negrar, Italy|AOU S. Luigi Orbassano, Orbassano, Italy|IRCCS ISTITUTO Oncologico Veneto, Padova, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|ASST Sette Laghi, Varese, Italy|AUOI di Verona- Borgo Trento, Verona, Italy",,https://ClinicalTrials.gov/show/NCT03896074,2,atezolizumab,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,atezolizumab,bevacizumab,1,1,TRUE,
431,1904,1905,NCT00442026,Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC,,Terminated,No Results Available,Non-small-cell Lung Cancer,Drug: Docetaxel|Drug: Gemcitabine,Overall survival between the two treatment arms|Overall response rate|Time to disease progression|Quality of life assessment|Toxicity profile,Hellenic Oncology Research Group|University Hospital of Crete,All,70 Years to 85 Years   (Older Adult),Phase 3,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/06.11,6-Dec,10-May,10-May,1-Mar-07,,27-Jun-12,"University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO"" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece|Sotiria"" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|""Metaxa's"" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion"" Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00442026,2,docetaxel,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,gemcitabine,1,1,TRUE,
432,1914,1915,NCT00965731,"Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer",,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Erlotinib|Drug: PF-02341066,"Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1)|Progression-Free Survival (Phase 2)|PF-02341066 (Crizotinib) Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)|PF-02341066 (Crizotinib) Maximum Observed Plasma Concentration (Cmax) (Phase 1)|PF-02341066 (Crizotinib) Apparent Oral Clearance (CL/F) (Phase 1)|PF-06260182 Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)|PF-06260182 Maximum Observed Plasma Concentration (Cmax) (Phase 1)|Molecular Weight Adjusted PF-06260182-to-PF-02341006 Ratio of AUCtau (Phase 1)|Erlotinib Area Under the Concentration-Time Curve During Dosing Interval (AUCtau) (Phase 1)|Erlotinib Maximum Observed Plasma Concentration (Cmax) (Phase 1)|Erlotinib Apparent Oral Clearance (CL/F) (Phase 1)|Ratio of Adjusted Means of Erlotinib AUCtau (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)|Ratio of Adjusted Means of Erlotinib Cmax (Crizotinib + Erlotinib / Erlotinib Alone) (Phase 1)|Progression-Free Survival (Phase 1)|Duration of Response (Phase 1)|Percentage of Participants With Objective Response (Phase 1)|Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 1)|Plasma Level of Soluble Marker: Hepatocyte Growth Factor (HGF) Scatter Factor (Phase 1)|Plasma Level of Soluble Marker: c-Met Ectodomain (Phase 2)|Plasma Level of Soluble Marker: HGF Scatter Factor (Phase 2)|Duration of Response (Phase 2)|Percentage of Participants With Confirmed CR, PR or Stable Disease (SD) at Phase 2|Percentage of Participants With Objective Response (Phase 2)|Overall Survival (OS) at Phase 2|European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire (QLQ-C30) Score at Phase 2|EORTC Quality of Life Questionnaire -Lung Cancer 13 (QLQ-LC13) Score at Phase 2|Plasma Concentration of PF-02341066 and Erlotinib (Phase 2)|Plasma Concentration of Erlotinib (Phase 2)|Percentage of Participants With Mutations in Tumor Tissue (Phase 2)",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,27,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A8081002|2009-012377-35,10-Jan,11-Dec,14-Jan,26-Aug-09,14-Jan-13,28-Oct-15,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, Irvine Medical Center Pharmacy, Orange, California, United States|University of California, Irving - Medical Center, Orange, California, United States|University of California Irvin, Orange, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Siteman Cancer Center -West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Washington University, School of Medicine, St. Louis, Missouri, United States|Siteman Cancer Center, St. Peters, Missouri, United States|OSU East, Columbus, Ohio, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|James Care in Kenny, Columbus, Ohio, United States|Cancer Therapy & Research Center @ UTHSCSA, San Antonio, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00965731,2,erlotinib,pf-02341066,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,crizotinib,1,1,TRUE,
438,1933,1934,NCT00637910,Tarceva Italian Lung Optimization tRial,TAILOR,Unknown status,No Results Available,Non Small Cell Lung Cancer (NSCLC),Drug: Erlotinib|Drug: Docetaxel,"Overall Survival|Progression Free Survival|Response assessed with RECIST criteria|Quality of Life assessed with QLQ-C30 and QLQ-LC13 questionnaires|Toxicity, graded according to the NCI-CTAE version 3.0|Frequency and nature of serious adverse reactions|Premature withdrawals",Fatebenefratelli and Ophthalmic Hospital|Mario Negri Institute for Pharmacological Research|Niguarda Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,850,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FARM6F5JER|2007-004786-17,7-Nov,12-Feb,13-Feb,18-Mar-08,,24-Feb-12,"Ospedale Civili Riuniti Giovanni Paolo II, Sciacca, Agrigento, Italy|Fabriano Hospital, Fabriano, Ancona, Italy|Ospedali Riuniti Umberto I - Lancisi - Salesi, Torrette, Ancona, Italy|Oncologia A.S.L. AV1, Ariano Irpino, Avellino, Italy|Pesenti-Fenaroli Hospital, Alzano Lombardo, Bergamo, Italy|Ospedale di Vipiteno, Vipiteno, Bolzano, Italy|Oncologia Medica Azienda Spedali Civili, Brescia, BS, Italy|Pneumologia Azienda Spedali Civili, Brescia, BS, Italy|Ospedale centrale di Bolzano, Bolzano, BZ, Italy|Policlinico Universitario di Monserrato, Monserrato, Cagliari, Italy|Ospedale Santa Barbara, Iglesias, Carbonia Iglesias, Italy|Renzetti Hospital, Lanciano, Chieti, Italy|Ospedale S. Elia, Caltanissetta, CL, Italy|San Francesco Hospital, Paola, Cosenza, Italy|Ospedale Civile di Saluzzo Savigliano, Saluzzo, Cuneo, Italy|Istituto Toscano Tumori Ospedale S. Giuseppe Antica Sede, Empoli, Firenze, Italy|Monfalcone Hospital, Monfalcone, Gorizia, Italy|Ospedale Civile Ferrari, Casarano, Lecce, Italy|Ospedale Civile di Casalpusterlengo, Casalpusterlengo, Lodi, Italy|Ospedale S. Maria Goretti, Latina, LT, Italy|B. Eustachio Hospital, San Severino Marche, Macerata, Italy|San Vincenzo Hospital, Taormina, Messina, Italy|Azienda Ospedaliera Melegnano- P.O. Gorgonzola, Gorgonzola, Milano, Italy|Legnano Hospital, Legnano, Milano, Italy|Ospedale Civile di Legnano -Presidio di Magenta, Magenta, Milano, Italy|San Gerardo Hospital, Monza, Milano, Italy|Rho Hospital - Azienda Ospedaliera Salvini-Garbagnate, Rho, Milano, Italy|Policlinico San Donato, San Donato Milanese, Milano, Italy|IRCCS Multimedica, Sesto San Giovanni, Milano, Italy|Ospedale Civile di Vimercate, Vimercate, Milano, Italy|Vizzolo Predabissi Hospital, Vizzolo Predabissi, Milano, Italy|San Leonardo Hospital, Gragnano, Napoli, Italy|Ospedale Civile Vigevano, Vigevano, Pavia, Italy|Policlinico Universitario Palermo, Palermo, PA, Italy|San Massimo Hospital, Penne, Pescara, Italy|Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Umberto I Hospital, Lugo, Ravenna, Italy|Ospedale Civile di Siderno - ASL n°9 Locri, Siderno, Reggio Calabria, Italy|S. Sebastiano Hospital, Correggio, Reggio Emilia, Italy|Ospedale di Scandiano, Scandiano, Reggio Emilia, Italy|S. Giovanni Evangelista Hospital, Tivoli, Roma, Italy|ASL SA1 -P.O. Umberto I, Nocera Inferiore, Salerno, Italy|Presidio Ospedaliero San Luca, Vallo della Lucania, Salerno, Italy|Ospedale Valdichiana ""Nottola"", Montepulciano, Siena, Italy|Ospedale Valdelsa ""Campostaggia"", Poggibonsi, Siena, Italy|Ospedale di Terni, Terni, TR, Italy|Multimedia Santa Maria, Castellanza, Varese, Italy|Azienda Ospedaliera Busto Arsizio, Saronno, Varese, Italy|Umberto I Hospital, Mestre, Venezia, Italy|Ospedale Mater Salutis, Legnago, Verona, Italy|Ospedale Policlinico G.B. Rossi, Verona, VR, Italy|S. Giovanni di Dio Hospital, Agrigento, Italy|Ospedale San Donato, Arezzo, Italy|Azienda Ospedaliera Universitaria Consorziale Policlinico, Bari, Italy|Fatebenefratelli Hospital, Benevento, Italy|G. Rummo Hospital, Benevento, Italy|Ospedali Riuniti, Bergamo, Italy|Armando Businco Oncological Hospital, Cagliari, Italy|Presidio Ospedaliero Cardarelli ASL 3, Campobasso, Italy|Sant'Anna Hospital, Como, Italy|Mariano Santo Hospital, Cosenza, Italy|Ospedale Maggiore di Crema, Crema, Italy|S. Croce e Carle Hospital, Cuneo, Italy|A.O.U. S. Anna, Ferrara, Italy|A.O.U. Careggi, Firenze, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|A.O. San Martino, Genova, Italy|Galliera Hospital, Genova, Italy|F. Veneziale Hospital, Isernia, Italy|Azienda Ospedaliera di Lecco, Lecco, Italy|Fatebenefratelli and Ophthalmic Hospital, Milano, Italy|Fondazione Ospedale Maggiore Policlinico - Mangiagalli e Regina Elena, Milano, Italy|San Paolo Hospital, Milano, Italy|San Carlo Borromeo Hospital, Milano, Italy|Azienda Ospedaliera Luigi Sacco Polo Universitario, Milano, Italy|A.O. Monaldi, Napoli, Italy|Cardarelli Hospital, Napoli, Italy|D. Cotugno Hospital, Napoli, Italy|San Gennaro Hospital - ASL NA 1, Napoli, Italy|Ospedale Maggiore della Carità, Novara, Italy|Azienda Ospedaliera Universitaria Presidio ""Paolo Giaccone"", Palermo, Italy|Presidio Ospedaliero ""M. Ascoli"" ARNAS Civico, Palermo, Italy|Centro Oncologico ""La Maddalena"", Palermo, Italy|S. Maria della Misericordia Hospital, Perugia, Italy|Piacenza Hospital, Piacenza, Italy|S. Maria degli Angeli Hospital, Pordenone, Italy|Ospedale Civile Santa Maria delle Croci, Ravenna, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Ospedale San Pietro Fatebenefratelli, Roma, Italy|Pneumologia Oncologica II-San Camillo Forlanini Hospital, Roma, Italy|Oncologia Medica-San Camillo Forlanini Hopsital, Roma, Italy|Università Campus Bio-Medico, Roma, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Umberto I, Roma, Italy|S. Giovanni - Addolorata Hospital, Roma, Italy|Azienda Ospedaliera S. Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy|Ospedale Civile SS. Annunziata, Sassari, Italy|Universita' di Sassari Oncologia Medica, Sassari, Italy|Ospedale Morelli, Sondrio, Italy|Sondrio Hospital-Azienda Ospedaliera Valtellina e Valchiavenna, Sondrio, Italy|A.O.U. San Giovanni Battista Molinette, Torino, Italy|Ospedale di Circolo, Varese, Italy|SS. Giovanni e Paolo Hospital, Venezia, Italy|San Bartolo Hospital, Vicenza, Italy|Belcolle Hospital, Viterbo, Italy",,https://ClinicalTrials.gov/show/NCT00637910,2,erlotinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,docetaxel,1,1,TRUE,
443,1944,1945,NCT04148898,Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis,OWONBNSCLCLM,Not yet recruiting,No Results Available,Leptomeningeal Metastasis|Non-small Cell Lung Cancer|EGFR Activating Mutation,Drug: Osimertinib|Drug: Bevacizumab,Intracranial progression-free|Objective Response Rate|LM Overall survival|progression-free survival|adverse events,Second Affiliated Hospital of Nanchang University|Nanchang University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,YC2019-S087,1-Nov-19,1-Mar-21,1-Jul-21,4-Nov-19,,4-Nov-19,,,https://ClinicalTrials.gov/show/NCT04148898,2,osimertinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,osimertinib,bevacizumab,1,1,TRUE,
447,1969,1970,NCT03299088,Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,,Recruiting,No Results Available,KRAS Gene Mutation|Metastatic Non-Squamous Non-Small Cell Lung Carcinoma|Recurrent Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7,Biological: Pembrolizumab|Drug: Trametinib,Incidence of dose-limiting toxicity (DLT) of pembrolizumab and trametinib per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0|Overall response rate (ORR)|Progression-free survival (PFS),"University of California, Davis|Merck Sharp & Dohme Corp.|Novartis|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,42,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1099442|UCDCC#259|P30CA093373|NCI-2017-01633,26-Jun-18,1-Sep-20,1-Mar-21,2-Oct-17,,12-Jun-19,"University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03299088,2,pembrolizumab,trametinib,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,trametinib,1,1,TRUE,
450,1974,1975,NCT02451930,A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,,Completed,No Results Available,Stage IV Non-Small Cell Lung Cancer,Drug: Necitumumab|Drug: Pembrolizumab,"Number of Participants with Dose Limiting Toxicities (DLTs) in Part A and C|Objective Response Rate (ORR) in Part B: Proportion of Participants With a Complete or Partial Response|Objective Response Rate (ORR) in Part A and C: Proportion of Participants With a Complete or Partial Response|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab|Number of Participants with Anti-Necitumumab Antibodies|Disease Control Rate (DCR) in Part B: Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD)|Duration of Response (DoR) in Part B|Progression Free Survival (PFS) in Part B|Overall Survival (OS) in Part B",Eli Lilly and Company|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,75,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15568|I4X-MC-JFCQ|2015‐001291‐22|KEYNOTE -099,4-Sep-15,26-Jan-17,17-Sep-19,22-May-15,,4-Oct-19,"Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon Cedex 08, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Herblain Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chuo-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sunto-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badajoz, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02451930,2,necitumumab,pembrolizumab,1,1,FALSE,FALSE,FALSE,FALSE,necitumumab,pembrolizumab,1,1,TRUE,
451,1976,1977,NCT01410214,Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations,,Unknown status,No Results Available,Non-small Cell Lung Cancer Stage IIIA,Drug: Erlotinib|Drug: vinorelbine/cisplatin,Disease-free survival|Number of Participants with Adverse Events|Quality of Life (QOL)|overall survival (OS),Chinese Lung Cancer Surgical Group|Tianjin Medical University Cancer Institute and Hospital|Fudan University|Zhejiang Cancer Hospital|Beijing Cancer Hospital|Sun Yat-sen University|Chinese PLA General Hospital|Qingdao University|The First Affiliated Hospital of Soochow University|Harbin Medical University|Hebei Medical University Fourth Hospital|The Second People's Hospital of Sichuan,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-LCSG-001,11-May,15-Jul,17-Jul,5-Aug-11,,23-Dec-11,"Beijing Cancer Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiurted Hospital of Soochow University, Suzhou, Jiangsu, China|Qingdao University Medical College, Qingdao, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|The Second People's Hospital of Sichuan, Chengdu, Sichuang, China|Tianjin Medical University Cancer Institute and Hospital, Tianji, Tianji, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT01410214,2,erlotinib,vinorelbine/cisplatin,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,vinorelbine/cisplatin,1,1,FALSE,Cisplatin is not an approved drug
452,1980,1981,NCT00284778,Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer,,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Alimta®|Drug: Taxotere®,,"University Hospital, Limoges|Groupe Francais De Pneumo-Cancerologie",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I05026,6-Feb,9-Dec,9-Dec,1-Feb-06,,29-Mar-10,"Service de Pneumologie, CHU Angers, Angers, France|Service de pneumologie; Centre Hospitalier d'Annecy, Annecy, France|Service de Pneumologie; Centre Hospitalier, Beauvais, France|Service de Pneumologie ; Centre hospitalier, Charleville-Mezieres, France|Service de Pneumologie; Centre Hospitalier, Draguignan, France|Service de Pathologie Respiratoire; CHU de Limoges, Limoges, France|Service de Pneumologie; Hôpital de la Croix Rousse, Lyon, France|Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay, Mantes La Jolie, France|Département des Maladies Respiratoires ; Hôpital Sainte Marguerite, Marseille, France|Service de Pneumologie et Réanimation ; Hôpital Hôtel Dieu - Paris, Paris, France|Service de Pneumologie - Hôpital St Antoine, Paris, Paris, France|Service de Pneumologie ; Hôpital saint Antoine, Paris, Paris, France|Service de Pneumologie-Allergologie; Centre Hospitalier Général, Perigueux, France|Service de Pneumologie; CHG de Roanne, Roanne, France|Clinique Pneumologique; Hôpital Charles Nicolle, Rouen, France|Service de Pneumologie; Hôpital Bois Guillaume, Rouen, France|Service de Pathologie Respiratoire; Hôpital d'Instruction des Armées Sainte-Anne, Toulon Naval, France|Service d'Oncologie Médicale; Clinique Sainte Marguerite, Toulon, France",,https://ClinicalTrials.gov/show/NCT00284778,2,alimta®,taxotere®,1,1,FALSE,FALSE,FALSE,FALSE,alimta®,taxotere®,1,1,TRUE,
455,1995,1996,NCT01955421,Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc,NSCLC EGFR TKI,Unknown status,No Results Available,Advanced Stage Non Small Cell Lung Cancer,Drug: Erlotinib 100mg qd|Drug: Gefitinib 250mg qd,disease control rate|progression free survival|adverse events,Sun Yat-sen University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,224,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E100VG250|Tarceva100vsIressa250,13-Jul,16-Jun,,7-Oct-13,,3-Jul-15,"Department of Medical Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01955421,2,erlotinib 100mg qd,gefitinib 250mg qd,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gefitinib,1,1,TRUE,
459,2006,2007,NCT00076388,Iressa Versus Docetaxel (Taxotere),,Completed,No Results Available,Non-Small-Cell Lung Carcinoma,Drug: Gefitinib|Drug: Docetaxel,To compare overall survival between ZD1839 and docetaxel|To compare time to progression (TTP) between ZD1839 and docetaxel|To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel|To compare the overall objective tumor response rate between ZD1839 and docetaxel|To compare patient-reported functionality (PRF) and quality of life (QoL) between ZD1839 and docetaxel|To compare safety and tolerability of ZD1839 and docetaxel,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1440,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D791GC00001|EudraCT No: 2004-002943-28|1839IL/0721,4-Feb,7-Mar,7-Oct,23-Jan-04,,13-May-11,"Research Site, Birmingham, Alabama, United States|Research Site, Fountain Valley, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Stockton, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Boca Raton, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Macon, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Skokie, Illinois, United States|Research Site, Knoxville, Kentucky, United States|Research Site, St. Louis Park, Minnesota, United States|Research Site, Great Neck, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Racine, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research site, El Palomar, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Fe, Argentina|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Godinne, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Yvoir, Belgium|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, St. Catherines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Ste-Foy, Quebec, Canada|Research Site, Beijing, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Aalborg, Denmark|Research Site, Arhus C, Denmark|Research Site, Glostrup, Denmark|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Vejle, Denmark|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Blois, France|Research Site, Boulogne Billancourt, France|Research Site, Caen Cedex, France|Research Site, Grenoble Cedex 09, France|Research Site, Le Mans, France|Research Site, Lille Cedex, France|Research Site, Nantes, France|Research Site, Niort, France|Research Site, Saint Herblain, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Vesoul Cedex, France|Research Site, Heidelberg, Baden-Württemberg, Germany|Research Site, Ulm, Baden-Württemberg, Germany|Research Site, Cottbus, Brandenburg, Germany|Research Site, Frankfurt, Hessen, Germany|Research Site, Düsseldorf, Nordrhein-Westfalen, Germany|Research Site, Mainz, Rheinland-Pfalz, Germany|Research Site, Bad Segeberg, Schleswig-Holstein, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Großhansdorf, Germany|Research Site, Köln, Germany|Research Site, Leverkusen, Germany|Research Site, Löwenstein, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Stuttgart, Germany|Research Site, Wiesbaden, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Jakarta, Indonesia|Research Site, Yogyakarta, Indonesia|Research Site, La Torretta, Ancona, Italy|Research Site, Bari, BA, Italy|Research Site, Bergamo, BG, Italy|Research Site, Bologna, BO, Italy|Research Site, Cuneo, CN, Italy|Research Site, Catania, CT, Italy|Research Site, Forli', FO, Italy|Research Site, Melegnano, MI, Italy|Research Site, Rozzano, MI, Italy|Research Site, Modena, MO, Italy|Research Site, Parma, PR, Italy|Research Site, Torino, TO, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Riga, Latvia|Research Site, Kuala Lumpur, Malaysia|Research Site, Nilai, Malaysia|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, Torreon, Mexico|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Singapore, Singapore|Research Site, Ljubliana, Slovenia|Research Site, Elche, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Vitoria, Spain|Research Site, Zaragoza, Spain|Research Site, Goteborg, Sweden|Research Site, Luleå, Sweden|Research Site, Skövde, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Vasteras, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Bellinzona, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zürich, Switzerland|Research Site, Chiang Mai, Thailand|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00076388,2,gefitinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,docetaxel,1,1,TRUE,
460,2015,2016,NCT01673867,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC,CheckMate057,"Active, not recruiting",Has Results,Non-Squamous Cell Non-small Cell Lung Cancer,Biological: Nivolumab|Drug: Docetaxel,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|One-year Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) Rate at 12 Months|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",Phase 3,792,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-057|2012-002472-14,10-Oct-12,5-Feb-15,23-Jan-20,28-Aug-12,26-Feb-16,19-Dec-18,"Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|City Of Hope, Duarte, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Winthrop University Hospital Oncology/Hematology, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Clinic, Ltd, Sayre, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Columbia Basin Hematology And Oncology, Kennewick, Washington, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Tweed Heads, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Praha 8, Czechia|Local Institution, Creteil, France|Local Institution, Dijon Cedex, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Parma, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Oslo, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Vizcaya, Spain|Local Institution, Chur, Graubuenden, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland",,https://ClinicalTrials.gov/show/NCT01673867,2,nivolumab,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,nivolumab,docetaxel,1,1,TRUE,
462,2020,2021,NCT01783834,Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients,,Completed,No Results Available,Previous Treated Metastatic Non-small Cell Lung Cancer,Drug: Gefitinib|Drug: Pemetrexed,Overall response rate|Progression free survival,Gachon University Gil Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,95,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008-GIRBA-1739,8-Feb,14-Jun,14-Jun,5-Feb-13,,11-Feb-16,"Gachon university Gil Medical Center, Incheon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01783834,2,gefitinib,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,pemetrexed,1,1,TRUE,
478,2110,2111,NCT00003562,Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: carboplatin|Drug: docetaxel,,"Hope Cancer Institute, Inc.|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,Primary Purpose: Treatment,CDR0000066626|HCRN-007|NCI-V98-1469,Jul-98,,,21-May-04,,4-Dec-13,"Bethany Medical Center, Kansas City, Kansas, United States|Heartland Cancer Research Network, Kansas City, Kansas, United States",,https://ClinicalTrials.gov/show/NCT00003562,2,carboplatin,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,docetaxel,1,1,TRUE,
487,2138,2139,NCT00406276,Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer,,Terminated,Has Results,Lung Cancer,Drug: RAD001|Drug: Docetaxel,"Number of Subjects Showing Partial Response and Stable Disease With the Combination of RAD001 and Docetaxel.|Time to Progression:Time Period (in Months) From Study Entry Until Disease Progression, Death, or Last Date of Contact.",Emory University,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1342-2004,6-Nov,10-Dec,13-Feb,4-Dec-06,28-May-12,23-Aug-13,"Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT00406276,2,rad001,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,afinitor,docetaxel,1,1,TRUE,
501,2196,2197,NCT02590003,Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer,,Terminated,Has Results,"Carcinoma, Non-small Cell Lung",Drug: Carboplatin|Drug: Nab-paclitaxel,Treatment Failure-free Survival|Overall Response Rate|Progression-free Survival|Overall Survival|Grade 3-5 Adverse Events|Symptom Assessment (Measured by FACT-L Symptom Assessment Scale),Yale University,All,71 Years and older   (Older Adult),Phase 2,3,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1403013529,15-Nov,16-Sep,16-Sep,28-Oct-15,28-Feb-18,28-Feb-18,"Yale Cancer Center, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02590003,2,carboplatin,nab-paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,nab-paclitaxel,1,1,TRUE,
503,2206,2207,NCT02574598,MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients,,Enrolling by invitation,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: MK-3475|Drug: Docetaxel,Overall Response rate,Instituto Nacional de Cancerologia de Mexico,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAN/014/033/ICI,16-Jun,19-Oct,20-Oct,14-Oct-15,,21-Dec-18,"National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",,https://ClinicalTrials.gov/show/NCT02574598,2,mk-3475,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,docetaxel,1,1,TRUE,
504,2210,2211,NCT02864394,Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033),,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung",Biological: pembrolizumab 2 mg/kg|Drug: Docetaxel 75 mg/m^2,OS in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score 1 to 49%)|OS in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score ≥50%)|PFS per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score 1 to 49%)|PFS per RECIST 1.1 as Assessed by BICR in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score ≥50%)|Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score 1 to 49%)|DOR per RECIST 1.1 as Assessed by BICR in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score ≥50%)|Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score 1 to 49%)|ORR per RECIST 1.1 as Assessed by BICR in Participants with Tumors that are Positive for PD-L1 Expression (Tumor Proportion Score ≥50%)|Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinue Study Drug Due to an AE,Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,425,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3475-033|MK-3475-033,7-Sep-16,9-Sep-19,14-Oct-20,12-Aug-16,,20-Sep-19,,,https://ClinicalTrials.gov/show/NCT02864394,2,pembrolizumab 2 mg/kg,docetaxel 75 mg/m^2,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,docetaxel,1,1,TRUE,
513,2253,2254,NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).,,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Gefitinib|Drug: MEDI4736,"Escalation Phase: safety and tolerability: AEs, laboratory data, vital signs, ECG changes and Echo. Expansion Phase: safety and tolerability of the recommended dose for MEDI4736; AEs, laboratory data, vital signs, ECG changes and Echo.|To obtain a preliminary assessment of the anti-tumour activity of gefitinib in combination with MEDI4736 by evaluation of tumour response|To determine the immunogenicity of MEDI4736 in combination with gefitinib: anti-drug antibodies (ADAs)|To determine the pharmacokinetics of MEDI4736|To assess MEDI4736 pharmacodynamics in subjects receiving MEDI4736 in combination with gefitinib.|To determine overall survival (OS) in expansion Arm 1 and Arm 1a patients",MedImmune LLC|AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 1,56,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D791PC00001,24-Mar-14,31-Dec-21,31-Dec-21,14-Mar-14,,15-Oct-19,"Research Site, Tampa, Florida, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Chuo-ku, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02088112,2,gefitinib,medi4736,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,durvalumab,1,1,TRUE,
516,2263,2264,NCT03810807,Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer,,Recruiting,No Results Available,Metastatic Non-small Cell Lung Cancer,Drug: Dacomitinib|Drug: Osimertinib,maximum tolerated dose|Best overall response rate,Memorial Sloan Kettering Cancer Center,All,"19 Years and older   (Adult, Older Adult)",Phase 1,34,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-411,17-Jan-19,21-Jan,21-Jan,21-Jan-19,,23-May-19,"Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,https://ClinicalTrials.gov/show/NCT03810807,2,dacomitinib,osimertinib,1,1,FALSE,FALSE,FALSE,FALSE,dacomitinib,osimertinib,1,1,TRUE,
517,2271,2272,NCT01469000,A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC),,Completed,Has Results,"Carcinoma, Non Small Cell Lung",Drug: Gefitinib|Drug: Pemetrexed,"Progression Free Survival (PFS)|Time To Progressive Disease (TTPD)|Overall Survival (OS)|Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])|Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])|Duration of Response (DoR)|Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,195,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14034|H3E-CR-JMIT,12-Feb,15-Apr,17-Nov,10-Nov-11,28-Apr-16,10-Sep-19,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changchun, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sichuan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cheong Ju-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jhonghe City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Keelung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01469000,2,gefitinib,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,pemetrexed,1,1,TRUE,
535,2337,2338,NCT02737501,ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants,ALTA-1L,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer|Lung Cancer|Advanced Malignancies|Carcinoma,Drug: Brigatinib|Drug: Crizotinib,Progression-free Survival (PFS)|Objective Response Rate (ORR)|Intracranial ORR|Intracranial PFS|Overall Survival (OS)|Duration of Response|Time to Response (TTR)|Disease Control Rate (DCR)|Health-related Quality of Life (HRQoL)|Percentage of Participants with Adverse Events,Ariad Pharmaceuticals|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,275,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AP26113-13-301|U1111-1210-4363,26-May-16,31-Jul-20,31-Jul-20,14-Apr-16,,11-Apr-19,"USOR - Arizona Oncology Associates - Sedona, Sedona, Arizona, United States|Kaiser Permanente Bellflower Medical Offices, Bellflower, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers - Boulder, Boulder, Colorado, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Minnesota Oncology, Coon Rapids, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Oncology Hematology Care - Blue Ash, Cincinnati, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States|Saint George Hospital, Kogarah, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Monash Medical Centre, East Bentleigh, Victoria, Australia|Saint Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Universitatsklinium St. Polten, Sankt Polten, Lower Austria, Austria|Otto-Wagner-Spital Baumgartner Hohe, Vienna, Austria|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Odense University Hospital, Odense C, Denmark|Centre de Lutte Contre le Cancer Francois Baclesse, CAEN Cedex 5, Basse-normandie, France|Hopital Charles Nicolle, Rouen, Haute-normandie, France|Centre Hospitalier Intercommunal de Creteil, Creteil, Ile-de-france, France|Hopital Tenon, Paris, Ile-de-france, France|Centre Hospitalier Universitaire Hopital Nord, Marseille Cedex 20, Provence Alpes COTE D'azur, France|Hopital Albert Michallon, Grenoble Cedex 9, Rhone-alpes, France|Centre Leon Berard, Lyon, Rhone-alpes, France|Universitatsklinik Freiburg, Freiburg, Baden-wuerttemberg, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden-wuerttemberg, Germany|Pius Hospital Oldenburg, Oldenburg, Niedersachsen, Germany|Kliniken der Stadt Koeln gGmbH - Krankenhaus Merheim, Koln, Nordrhein-westfalen, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Studiengesellschaft Haemato-Onkologie Hamburg Prof. Laack und Partner, Hamburg, Germany|Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli-cesena, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, Monza E Brianza, Italy|Centro di Riferimento Oncologico di Aviano, Aviano, Pordenone, Italy|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Italy|Istituto Oncologico di Bari Giovanni Paolo II, Bari, Italy|Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Istituto Scientifico Universitario San Raffaele, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Tumori Napoli Fondazione G. Pascale, Napoli, Italy|Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Italy|Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia, Perugia, Italy|Azienda Unita Sanitaria Locale di Ravenna, Ravenna, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg - Hopital Municipal, Luxembourg, Luxembourg|Amphia Ziekenhuis - Locatie Langendijk Breda, Breda, Noord-brabant, Netherlands|Antoni van Leeuwenhoekziekenhuis, Amsterdam, Noord-holland, Netherlands|Isala Klinieken, Zwolle, Overijssel, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Radiumhospitalet, Oslo, Norway|National University Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|OncoCare Cancer Centre, Singapore, Singapore|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Teresa Herrera - Materno Infantil, La Coruna, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario Carlos Haya Malaga Instituto de Neurociencias Clinicas, Malaga, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset, Stockholm, Sweden|University Hospital Zurich, Zurich, Switzerland|National Cheng Kung University, Tainan, Taipei, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Leicester Royal Infirmary, Leicester, England, United Kingdom|University College London, London, England, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, England, United Kingdom|Royal Marsden NHS Trust, London, England, United Kingdom|Maidstone Hospital, Maidstone, England, United Kingdom|The Christie NHS Foundation Trust, Manchester, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT02737501,2,brigatinib,crizotinib,1,1,FALSE,FALSE,FALSE,FALSE,brigatinib,crizotinib,1,1,TRUE,
538,2343,2344,NCT04120454,Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer,,Not yet recruiting,No Results Available,Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Biological: Pembrolizumab|Biological: Ramucirumab,Overall response rate|Incidence of adverse events|Clinical benefit rate (complete response + partial response + stable disease)|Progression-free survival|Overall survival,Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,34,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSU-19132|NCI-2019-05348|P30CA016058,1-Dec-19,31-Dec-21,31-Dec-21,9-Oct-19,,9-Oct-19,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT04120454,2,pembrolizumab,ramucirumab,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,ramucirumab,1,1,TRUE,
541,2347,2348,NCT00193414,Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Drug: Pemetrexed|Drug: Gemcitabine,Overall Response Rate|Progression-free Survival (PFS)|Overall Survival (OS),"SCRI Development Innovations, LLC|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 2,74,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LUN 91|H3E-US-X011,5-May,8-Dec,9-Aug,19-Sep-05,13-Nov-12,13-Nov-12,"Tennessee Oncology, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00193414,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
544,2358,2359,NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician|Time to Progression|Overall Survival,"Nasser Hanna, M.D.|Genentech, Inc.|Walther Cancer Institute|Hoosier Cancer Research Network",All,"18 Years and older   (Adult, Older Adult)",Phase 2,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HOG LUN04-77,6-Aug,8-Apr,8-Dec,23-Aug-06,11-Feb-16,11-Feb-16,"Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States|Community Regional Cancer Center, Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Oncology Partners Network, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00367601,2,erlotinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,bevacizumab,1,1,TRUE,
548,2366,2367,NCT02036359,Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca,Oncology,Unknown status,No Results Available,Non-small Cell Lung Cancer(NSCLC),Drug: erlotinib|Drug: docetaxel,Number of Adverse Event,National Taiwan University Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201203009MIB,12-May,15-Jun,,15-Jan-14,,15-Jan-14,"Department of Oncology, National Taiwan University Hospital, Taipei,, Taiwan",,https://ClinicalTrials.gov/show/NCT02036359,2,erlotinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,docetaxel,1,1,TRUE,
552,2377,2378,NCT00193310,"Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer",,Completed,No Results Available,Lung Cancer,Drug: Paclitaxel|Drug: Carboplatin,Overall response rates|Resectability rates|Survival|Time to progression|Toxicity,"SCRI Development Innovations, LLC|Bristol-Myers Squibb|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 2,250,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LUN 53,Nov-00,3-Nov,9-Jan,19-Sep-05,,18-Mar-15,,,https://ClinicalTrials.gov/show/NCT00193310,2,paclitaxel,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,paclitaxel,carboplatin,1,1,TRUE,
553,2381,2382,NCT00061451,Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial,,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Pemetrexed|Drug: Gemcitabine,To assess the objective tumor response rate of gemcitabine plus pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.|To assess time to objective tumor response for responding patients|To assess duration of response for responding patients|To assess time to treatment failure for patients|To assess progression free survival of patients|To assess time to progressive disease for patients|To assess survival time for patients|To characterize the toxicities of gemcitabine plus pemetrexed in this patient population,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7213|H3E-US-JMFY,2-Dec,,6-Sep,29-May-03,,22-Dec-10,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palo Alto, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Great Falls, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00061451,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
554,2382,2383,NCT02733250,Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer,URCOH-PMS-001,"Active, not recruiting",No Results Available,Lung Cancer,Biological: Pembrolizumab|Drug: Nab-Paclitaxel,"Safety and tolerability of nab-paclitaxel in combination with pembrolizumab as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities.|Objective Response Rate (ORR)",Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Merck Canada Inc.|Celgene|Jewish General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,36,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CE15.274,13-Mar-17,20-Apr,20-Dec,11-Apr-16,,20-Jun-18,"Centre hospitalier de l'université de Montréal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02733250,2,pembrolizumab,nab-paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,pembrolizumab,nab-paclitaxel,1,1,TRUE,
562,2418,2419,NCT00193323,Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients,,Completed,No Results Available,Lung Cancer,Drug: Docetaxel|Drug: Gemcitabine,median survival|one-year survival.|toxicity,"SCRI Development Innovations, LLC|Aventis Pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 2,346,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCRI LUN 52|104864-450,1-Aug,6-May,9-Jan,19-Sep-05,,28-Jun-10,"Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00193323,2,docetaxel,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel,gemcitabine,1,1,TRUE,
571,2497,2498,NCT00174629,GILT Docetaxel - Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Neoplasms,Drug: Docetaxel/DDP|Drug: docetaxel/gemcitabine,"Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.|Time to treatment failure and survival|Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria.|Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening.",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,449,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAX_ES1_302,1-Jun,7-Jan,,15-Sep-05,,7-Dec-09,"Sanofi-Aventis, Berlin, Germany|Sanofi-Aventis, Barcelona, Spain|Sanofi-Aventis, Genève, Switzerland",,https://ClinicalTrials.gov/show/NCT00174629,2,docetaxel/ddp,docetaxel/gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,docetaxel/ddp,docetaxel/gemcitabine,1,1,FALSE,Ddp is not an approved drug
574,2517,2518,NCT03460678,Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.,,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Pemetrexed|Drug: Erlotinib,Progression-Free Survival (PFS) in eligible patients randomized to erlotinib or pemetrexed treatment arms|Median Overall Survival (OS) Time between eligible patients randomized to erlotinib or pemetrexed treatment of therapy|Overall response rate and duration between eligible patients randomized to erlotinib or pemetrexed treatment arms|Incidence of adverse events (AEs) and serious adverse events (SAEs) to erlotinib and pemetrexed,Hikma Pharmaceuticals LLC,All,"18 Years and older   (Adult, Older Adult)",Phase 4,72,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRT-JOR-LEB-KSA-2016-04,28-Feb-18,19-Dec,19-Dec,9-Mar-18,,19-Mar-18,"King Hussein Cancer Center (KHCC), Amman, Jordan|American University of Beirut Medical Center, Beirut, Lebanon",,https://ClinicalTrials.gov/show/NCT03460678,2,pemetrexed,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,erlotinib,1,1,TRUE,
579,2532,2533,NCT02511184,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,,Terminated,Has Results,ALK-positive Advanced NSCLC,Drug: Crizotinib|Drug: Pembrolizumab,"Number of Participants With Dose-limiting Toxicity (DLT)|Number of Participants With Treatment-Emergent Adverse Events|Objective Response Rate (ORR)|Duration of Response|Time to Tumor Response|Progression Free Survival|6-Month, 12-Month and 18-Month Progression Free Survival Probabilities|Overall Survival|12-Month and 18-Month Overall Survival Probabilities|Number of Participants With Maximum Grade in Laboratory Hematology Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment|Number of Participants With Maximum Grade in Laboratory Chemistry Test Shifting From Grade 0, 1 or 2 at Baseline to Grade 3 or 4 During Treatment|Plasma Concentration Summary of Crizotinib for ""Crizotinib + Pembrolizumab"" Group|Plasma Concentration Summary of Crizotinib for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Time to Maximum Plasma Concentration (Tmax) of Crizotinib for ""Crizotinib + Pembrolizumab"" Group|Time to Maximum Plasma Concentration (Tmax) of Crizotinib for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for ""Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve From 0 to 8 Hours (AUC0-8) of Crizotinib for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for ""Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of Crizotinib for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Apparent Plasma Clearance (CL/F) of Crizotinib for ""Crizotinib + Pembrolizumab"" Group|Apparent Plasma Clearance (CL/F) of Crizotinib for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Plasma Concentration Summary of PF-06260182 for ""Crizotinib + Pembrolizumab"" Group|Plasma Concentration Summary of PF-06260182 for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for ""Crizotinib + Pembrolizumab"" Group|Time to Maximum Plasma Concentration (Tmax) of PF-06260182 for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for ""Crizotinib + Pembrolizumab"" Group|Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUCtau) of PF-06260182 for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for ""Crizotinib + Pembrolizumab"" Group|Metabolite (PF-06260182) to Parent (Crizotinib) AUCtau Ratio for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for ""Crizotinib + Pembrolizumab"" Group|Metabolite (PF-06260182) to Parent (Crizotinib) Concentration Ratio for ""Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab"" Group|Serum Concentration of Pembrolizumab|Number of Participants With Programmed Death Receptor-1 Ligand-1 (PD-L1) Expression Level Meeting Pre-defined Criteria",Pfizer|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,A8081054|KEYNOTE 050|CRIZOTINIB,15-Oct,17-Dec,17-Dec,29-Jul-15,1-Jul-19,1-Jul-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, IDS Pharmacy, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States|UC San Diego Medical Center - La Jolla(Thornton Hospital), La Jolla, California, United States|University Of California / San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Investigational Drug Services Pharmacy, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02511184/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02511184/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02511184,2,crizotinib,pembrolizumab,1,1,FALSE,FALSE,FALSE,FALSE,crizotinib,pembrolizumab,1,1,TRUE,
581,2545,2546,NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,EMPHASIS,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Erlotinib|Drug: Docetaxel,Progression-free Survival|Overall Survival|Objective Response|Disease Control|Number of Participants With Adverse Events,"European Thoracic Oncology Platform|Biodesix, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,81,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ETOP3-12|2012-001896-35,12-Aug,15-Dec,15-Dec,30-Jul-12,8-Aug-19,24-Oct-19,"Krankenhaus Hietzing, Wien, Austria|Institut Jules Bordet, Brussels, Belgium|Aarhus University Hospital, Aarhus, Denmark|University Hospital of Heraklion, Heraklion, Greece|National Institute of Oncology, Budapest, Hungary|St James's Hospital, Dublin, Ireland|Institution Rabin MC, Petah Tikwa, Israel|Tel-Aviv Medical Center, Tel-Aviv, Israel|Medical Oncology, Second University Naples, Naples, Italy|Vercelli Teaching Hospital, Vercelli, Italy|Free University Medical Center, Amsterdam, Netherlands|Hospital general de Alicante, Alicante, Spain|Hospital Clínic Barcelona, Barcelona, Spain|Institut Català d'Oncologia - L'Hospitalet, Barcelona, Spain|Ciudad Real General University Hospital, Ciudad Real, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Onkologikoa, Donostia, Spain|Hospital Severo Ochoa, Leganés, Spain|Hospital 12 de Octubre, Madrid, Spain|Carlos Haya Hospital, Malaga, Spain|Hospital Universitari Sant Joan, Reus, Spain|Hospital Arnau Vilanova Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Fondation du centre Pluridisciplinaire d'Oncologie (CePO), Lausanne, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Onkologiezentrum Berner Oberland, Thun, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|University Hospital South Manchester, Manchester, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01652469/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01652469/ICF_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01652469/SAP_002.pdf|""Statistical Analysis Plan: moc figures SAP"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01652469/SAP_003.pdf|""Statistical Analysis Plan: moc tables SAP"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01652469/SAP_004.pdf",https://ClinicalTrials.gov/show/NCT01652469,2,erlotinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,docetaxel,1,1,TRUE,
589,2581,2582,NCT00489983,Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: pemetrexed|Drug: gemcitabine,"To evaluate efficacy.|To evaluate toxicity.|To evaluate response.|To evaluate overall survival, duration of overall response, and duration of stable disease.",Eli Lilly and Company,All,70 Years and older   (Older Adult),Phase 2,91,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5119|H3E-EW-JMEM,3-Jul,,5-Mar,22-Jun-07,,22-Jun-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00489983,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
598,2627,2628,NCT01755923,Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC,,Unknown status,No Results Available,Non-small Cell Lung Cancer,Drug: Gefitinib|Drug: Docetaxel,Progression free survival|Overall survival|Objective response rate|the score of functional assessment of cancer treatment-lung (FACT-L)|Number of participants with adverse events,Peking Union Medical College Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PUMCH-S466,12-Dec,13-Dec,14-Dec,24-Dec-12,,24-Dec-12,"Department of Respiratory Medicine, Peking Union Medical College Hospita, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01755923,2,gefitinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,docetaxel,1,1,TRUE,
599,2629,2630,NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer|EGFR-mutant Lung Cancers,Drug: osimertinib|Drug: Bevacizumab,maximum tolerated dose (MTD) (Phase I)|progression-free survival (Phase II),"Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc.",All,"19 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-033,29-Jun-16,20-Jun,20-Jun,16-Jun-16,,5-Sep-19,"Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,https://ClinicalTrials.gov/show/NCT02803203,2,osimertinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,osimertinib,bevacizumab,1,1,TRUE,
600,2635,2636,NCT02496663,Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,,Recruiting,No Results Available,Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7,Biological: Necitumumab|Drug: Osimertinib,Maximum tolerated dose (MTD) of necitumumab combined with osimertinib|Incidence of toxicity|Objective response rate (ORR) in patients treated at the recommended phase II dose|Progression-free survival (PFS)|Disease control rate (DCR) with combination osimertinib and necitumumab,National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,100,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2015-01053|PHI-77|9898|UM1CA186717,24-Mar-16,30-Jun-20,,14-Jul-15,,8-Nov-19,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Cancer Institute Cary, Cary, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02496663,2,necitumumab,osimertinib,1,1,FALSE,FALSE,FALSE,FALSE,necitumumab,osimertinib,1,1,TRUE,
610,2698,2699,NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Lorlatinib|Drug: Crizotinib,"Progression-free survival (PFS) based on blinded independent central review (BICR) assessment|Overall Survival (OS)|PFS based on Investigator's assessment|Objective Response (OR) based on BICR and on Investigator's assessments|Intracranial Objective Response (IC-OR) based on BICR assessment|Intracranial Time to Progression (IC-TTP) based on BIRC assessment|Duration of Response (DR) based on BIRC assessment|intracranial Duration of Response (IC-DR) based on BICR assessment|Time to Tumor Response (TTR) based on BIRC assessment|Intracranial Time to Tumor Response (IC-TTR) based on BICR assessment|PFS2 based on investigator's assessment|Adverse Event (AE) as graded by NCI CTCAE v 4.03)|Laboratory abnormalities as graded by NCI CTCAE v 4.03)|Vital signs (blood pressure, pulse rate) and body weight|Electrocardiograms (ECG)|Echocardiograms or multigated acquisition scan (MUGA)|Ophthalmology|PRO as assessed by EORTC QLQ-C30, EORTC QLQ LC13, and EQ-5D-5L|Tumor tissue biomarkers|Peripheral blood cfDNA (circulating free Deoxyribonucleic acid) biomarkers",Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,280,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B7461006|2016-003315-35,14-Apr-17,14-Feb-20,1-Feb-24,14-Feb-17,,8-Nov-19,"Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Florida Cancer Specialists, Ocala, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, The Villages, Florida, United States|Florida Cancer Specialists, Winter Park, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro Medico Austral, Caba, Argentina|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Department of Respiratory,the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Guangdong General Hospital, Guangzhou, China|Fakultni nemocnice Olomouc, Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Fakultni nemocnice Olomouc, Lekarna, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Vseobecna fakultni nemocnice v Praze, Lekarna, OVV III, Praha2, Czechia|Hopital Haut-Léveque-Centre François Magendie, Pessac, Aquitaine, France|Hopital Haut-Léveque, Pessac, Aquitaine, France|Hopital de Chevilly Larue, Chevilly Larue, France|Centre Hospitalier du Mans, Le Mans, France|Institut Paoli-Calmettes, Marseille cedex 09, France|Département d'Imagerie Médicale, Marseille cedex 20, France|Hôpital Nord, Marseille cedex 20, France|Service Ophtalmologie, Marseille cedex 20, France|Clinique Monticelli-Paradis-Dr Stephan Fauquier, Marseille, France|Pharmacie - Essais Cliniques, Marseille, France|Groupe Hospitalier Bichat Claude Bernard, AP-HP, Paris, France|CHU de Rennes Hopital Pontchaillou, Rennes cedex 9, France|CHU de Rennes, Hopital Pontchaillou, Rennes cedex 9, France|Hopital Foch, Suresnes, France|Service d'imagerie medicale, Suresnes, France|Service d'Ophtalmologie, Suresnes, France|Service Pharmacie-Essais Cliniques, Suresnes, France|Hopital Pierre Paul Riquet, Toulouse cedex 9, France|Hôpital Larrey, Toulouse cedex 9, France|lnstitut Claudius Regaud, Toulouse cedex 9, France|Hopital Larrey, Toulouse, France|Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France|Department d'imagerie medicale, Villejuif, France|Institut Gustave Roussy, Villejuif, France|Uberortliche Radiologische Gemeinschaftspraxis Dr. med. Marc Amler, Dresden, Germany|Technische Universitat Dresden , Medizinische Fakultat Carl Gustav Carus, Dresden, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitatsklinikum Regensburg, Institut fur Rontgendiagnostik, Regensburg, Germany|Universitatsklinikum Regensburg, Klinik und Poliklinik fur Innere Medizin II, Regensburg, Germany|The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong|The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Artemis Hospital, Gurgaon, Haryana, India|Manipal Hospital, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispeciality Hospitals India Pvt Ltd, Bangalore, Karnataka, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|ASST Monza - A.O. San Gerardo, Monza, MB, Italy|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Azienda Ospedaliera di Perugia - Ospedale S. M. Misericordia, Perugia, PG, Italy|Centro di Riferimento Oncologico-IRCCS, Aviano, PN, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, PR, Italy|AUSL della Romagna - Ospedale degli infermi, Faenza, RA, Italy|AUSL della Romagna - Ospedale ""Umberto I"", Lugo, RA, Italy|UO Farmacia Oncologica, Ravenna, RA, Italy|Istituto Nazionale Tumori Regina Elena - Istituto I.F.O., Roma, RM, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy|Servizio Farmacia, Roma, RM, Italy|Az.Osp.San Camillo-Forlanini, Roma, RM, Italy|Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, RM, Italy|Azienda Ospedaliera San Paolo - Polo Universitario, Milano, Italy|Azienda Ospedaliera Dei Colli Ospedale Monaldi, Napoli, Italy|Istituto Nazionale Tumori di Napoli, Napoli, Italy|Ausl della Romagna- Ravenna, Ravenna, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Department of Pulmonary Medicine and Oncology, Wakayama, Japan|Pharmacy, The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, St. Vincents Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Department of Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Clinical Trial Center, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Cancer Center Clinical Trial, Asan Medical Center, Seoul, Korea, Republic of|Department of Pharmacy, Ulsan University Hospital, Ulsan, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Promotora Medica Aguascalientes SA de CV, Aguascalientes, Mexico|CT scanner del Sur S.A. de C.V., Distrito Federal, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Distrito Federal, Mexico|Universitair Medisch Centrum Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii, Gdansk, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|RBHI Kursk Regional Clinical Oncology Dispensary, Kislino, Ryshkovsky Rural Council, Kursk Region, Russian Federation|Budgetary Healthcare Institution Omsk Region ""Clinical Oncological Dispensary"", Omsk, OMSK Region, Russian Federation|LEC at SBIH ""Saint-Petersburg Clinical Research Practical Center of specialized types of, Pesochniy Poselok, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|RBHI Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|FSBI ""N.N.Blokhin Medical Research Center of Oncology"", Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Institut Catala d'Oncologia L'Hospitalet, L'Hospitatel De Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario De Navarra, Pamplona, Navarra, Spain|Hospital Teresa Herrera C.H.U.A.C., A Coruna, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Dr. Josep Trueta, Girona, Spain|Institut Catala d'Oncologia Girona, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Clinical Trial Pharmacy, Chang Gung Medical Foundation - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital Clinical Trial Pharmacy, Taichung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Clinical Trial Pharmacy, Taichung Veterans General Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Clinical Trial Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Marmara Univ Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom|Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03052608,2,lorlatinib,crizotinib,1,1,FALSE,FALSE,FALSE,FALSE,lorlatinib,crizotinib,1,1,TRUE,
614,2712,2713,NCT03779191,Alectinib in Combination With Bevacizumab in ALK Positive NSCLC,,Not yet recruiting,No Results Available,ALK Gene Rearrangement Positive|Non-Squamous Non-Small Cell Neoplasm of Lung,Drug: Alectinib|Drug: Bevacizumab,Progression-free survival|Objective response rate|Brain- ORR|Overall survival|Time to developing brain metastases|Disease-related symptom improvement,Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Alectinib plus Bevacizumab,20-Mar-19,1-Jul-20,30-Jan-21,18-Dec-18,,21-Dec-18,,,https://ClinicalTrials.gov/show/NCT03779191,2,alectinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,alectinib,bevacizumab,1,1,TRUE,
616,2715,2716,NCT03909334,Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),,Recruiting,No Results Available,Non Small Cell Lung Cancer|EGFR Gene Mutation|Advanced Cancer|Metastatic Cancer,Drug: Osimertinib|Drug: Ramucirumab,Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease control rate (DCR)|Overall survival (OS)|Assess frequency and severity of adverse events,Xiuning Le|M.D. Anderson Cancer Center|Eli Lilly and Company|Hoosier Cancer Research Network,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HCRN LUN18-335,25-Jul-19,21-Jun,24-Jun,10-Apr-19,,15-Oct-19,"Moffitt Cancer Center, Tampa, Florida, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03909334,2,osimertinib,ramucirumab,1,1,FALSE,FALSE,FALSE,FALSE,osimertinib,ramucirumab,1,1,TRUE,
623,2756,2757,NCT01282151,TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer,TRAIL,Terminated,No Results Available,"Carcinoma, Non Small Cell Lung",Drug: Taxotere|Drug: Pemetrexed,Progression Free Survival|Overall Survival (months from the beginning of first cycle chemotherapy)|Safety Profile|Response rate,Chonnam National University Hospital|Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,148,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DOCET_L_05478,11-Jul,13-Dec,14-Dec,24-Jan-11,,14-Jul-15,"Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Kyungpook, Korea, Republic of|Hallym University Medical Center, Anyang, Korea, Republic of|Dankook University Hospital, Cheonan, Korea, Republic of|Keimyung University Dongsan Center, Daegu, Korea, Republic of|Yeungnam Univeristy Hospital, Daegu, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Kosin University Gospel Hospital, Pusan, Korea, Republic of|Konkuk university medical center, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Korea University Medical Center, Seoul, Korea, Republic of|Wonju Christian Hospital, Wonju, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01282151,2,taxotere,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,taxotere,pemetrexed,1,1,TRUE,
637,2812,2813,NCT01774721,ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.,ARCHER1050,"Active, not recruiting",Has Results,Non-small Cell Lung Cancer With EGFR-Activating Mutations,Drug: Dacomitinib (PF-00299804)|Drug: Gefitinib,"Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review|Progression Free Survival (PFS) Based on Investigator Assessment|Number of Participants With Best Overall Response (BOR) Based on IRC Review|Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment|Objective Response Rate (ORR) Based on IRC Review|Objective Response Rate (ORR) Based on Investigator Assessment|Duration of Response (DoR)|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology|Number of Participants With Laboratory Test Abnormalities: Urinalysis|Number of Participants With Clinically Significant Abnormalities in Vital Signs|Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)|Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)|Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough|Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)|Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265|Area Under the Plasma Concentration-Time Curve From Time 0 to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265|Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265|Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265|Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265|Apparent Clearance (CL) of Dacomitinib|Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265","SFJ Pharmaceuticals, Inc.|Pfizer|SFJ Lung Cancer Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,452,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DP312804,13-Apr,16-Jul,31-Dec-20,24-Jan-13,26-Oct-18,17-Apr-19,"Beijing, China|Changchun, China|Changsha, China|Chengdu, China|Chongqing, China|Fuzhou, China|Guangzhou, China|Hangzhou, China|Hefei, China|Nanning, China|Shanghai, China|Shenyang, China|Tianjin, China|Wuhan, China|Wuxi, China|Pokfulam, Hong Kong|Shatin, Hong Kong|Catania, Italy|Lecco, Italy|Livorno, Italy|Meldola, Italy|Milano, Italy|Napoli, Italy|Perugia, Italy|Ravenna, Italy|Roma, Italy|Trento, Italy|Viterbo, Italy|Hokkaido, Asahikawa, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Yokohama, Kanagawa, Japan|Tokyo, Koto-ku, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Sunto-gun, Shizouka, Japan|Chuo-Ku, Tokyo, Japan|Seoul, Korea, Republic of|Gdansk, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Avila, Spain|Barcelona, Spain|Bilbao, Spain|Caceres, Spain|Cordoba, Spain|Las Palmas, Spain|Madrid, Spain|Malaga, Spain|San Sebastian, Spain|Seville, Spain",,https://ClinicalTrials.gov/show/NCT01774721,2,dacomitinib (pf-00299804),gefitinib,1,1,FALSE,FALSE,FALSE,FALSE,dacomitinib,gefitinib,1,1,TRUE,
645,2841,2842,NCT03133546,Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER),BOOSTER,"Active, not recruiting",No Results Available,Non Small Cell Lung Cancer Metastatic,Drug: Osimertinib|Drug: Bevacizumab,Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control|Adverse Events|Overall Survival (OS),European Thoracic Oncology Platform|AstraZeneca|Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,155,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ETOP 10-16|2016-002029-12|ESR-15-11666|MO39447,31-May-17,22-May,22-May,28-Apr-17,,21-May-19,"St. James Hospital, Dublin, Ireland|Mid Western Cancer Centre, Limerick, Ireland|National Cancer Centre, Goyang, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|VU University Medical Centre, Amsterdam, Netherlands|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Hospital General Alicante, Alicante, Spain|Hospital Sant Pau, Barcelona, Spain|ICO Badalona, Barcelona, Spain|ICO Hospitalet, Barcelona, Spain|OSI Bilbao Basurto, Bilbao, Spain|Hospital Teresa Herrara, La Coruna, Spain|Fund. Jimenez Diaz, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital la Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Geneva University Hospital (HUG), Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|UniversitatSpital Zurich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT03133546,2,osimertinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,osimertinib,bevacizumab,1,1,TRUE,
646,2843,2844,NCT02393625,Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,,"Active, not recruiting",No Results Available,ALK-positive NSCLC,Drug: Ceritinib (LDK378)|Drug: Nivolumab,Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion|Overall response rate (ORR)|Duration of Response (DOR)|Disease Control Rate (DCR)|Time to Response (TTR)|Progression Free Survival (PFS)|Overall survival (OS),Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 1,57,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLDK378A2120C,27-May-15,5-Jun-20,5-Jun-20,19-Mar-15,,23-Jul-19,"Mayo Clinic - Arizona, Scottsdale, Arizona, United States|Massachusetts General Hospital Thoracic Oncolgoy, Boston, Massachusetts, United States|Fox Chase Cancer Center StudyCoordinator, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT02393625,2,ceritinib (ldk378),nivolumab,1,1,FALSE,FALSE,FALSE,FALSE,ceritinib,nivolumab,1,1,TRUE,
650,2857,2858,NCT03596866,An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib,ALTA-3,Recruiting,No Results Available,ALK+ Advanced NSCLC,Drug: Brigatinib|Drug: Alectinib,PFS as Assessed by Blinded Independent Review Committee (BIRC) per RECIST v1.1|Time to Intracranial Progression (iPD) as Assessed by BIRC per Modified RECIST v1.1|Overall Survival (OS)|Objective Response Rate (ORR) as Assessed by Investigator and BIRC per RECIST v1.1|Time to Response as Assessed by Investigator and BIRC|Duration of Response (DOR) as Assessed by BIRC|Intracranial Objective Response Rate (iORR) as Assessed by BIRC per Modified RECIST v1.1|Intracranial Duration of Response (iDOR) as Assessed by the BIRC per Modified RECIST v1.1|Health-Related Quality of Life (HRQOL) from European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score|HRQOL from EORTC QLQ- Lung Cancer (LC) 13,Ariad Pharmaceuticals|Takeda,All,"18 Years and older   (Adult, Older Adult)",Phase 3,246,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Brigatinib-3001|2018-001957-29,19-Apr-19,4-Dec-21,5-Dec-22,24-Jul-18,,25-Oct-19,"The Oncology Institute of Hope and Innovation, Whittier, California, United States|University Cancer and Blood Center, Athens, Georgia, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Centro Para la Atencion Integral del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Sanatorio Duarte Quiros, Cordoba, Argentina|Instituto Alexander Fleming, Cuidad Autonoma de Buenos Aires, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Klinikum Klagenfurt Am Worthersee, Klagenfurt Am Woerthersee, Carinthia, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Vienna, Austria|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Toronto University Health Network, Toronto, Ontario, Canada|Red Hospital Clinico de La Universidad de Chile, Santiago, Region Metropolitana, Chile|Centro de Investigacion Clinica Bradford Hill, Recoleta, Santiago, Chile|Beijing Chest Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital - East, Beijing, Beijing, China|The 307th Hospital of Chinese Peoples Liberation Army, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Peking University Cancer Hospital/Beijing Cancer Hospital, Hai-Dian, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Affiliated Tumor Hospital of Harbin Medical University - The 3rd Affiliated Hospital of HMU, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Jilin Provincial Cancer Hospital (Changchun Cancer Hospital), Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Opca bolnica Dubrovnik, Dubrovnik, Dubrovnik-Neretva, Croatia|General Hospital Pula, Pula, Croatia|Klinicki bolnicki centar Sestre milosrdnice, Zagreb, Croatia|Klinika za Pulmologiju, Zagreb, Croatia|Hopital Haut-Leveque, Pessac, Aquitaine, France|Centre Hospitalier Intercommunal de Creteil, Creteil, Ile-de-france, France|Hopital Foch, Suresnes, Ile-de-france, France|Gustave Roussy, Villejuif cedex, Ile-de-france, France|Centre Hospitalier Universitaire de Toulouse- Hopital Larrey, Toulouse Cedex 9, Midi-pyrenees, France|Centre Hospitalier Le Mans, Le Mans Cedex 9, PAYS DE LA Loire, France|Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer, Toulon, Provence Alpes COTE D'azur, France|Hopital Albert Michallon, Grenoble Cedex 9, Rhone-alpes, France|Thoraxklinik Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Asklepios Fachkliniken Munchen-Gauting, Gauting, Bayern, Germany|Klinikum Kempten-Oberallgau, Immenstadt, Bayern, Germany|Sotiria General Hospital for Respiratory Diseases of Attica, Mesogeion, Athens, Greece|University General Hospital of Athens Attikon, Athens, Attica, Greece|Iaso General Hospital, Cholargos, Attica, Greece|General Oncology Hospital of Kifisia Oi Agioi Anargiroi, Nea Kifisia, Attica, Greece|Interbalkan Medical Center of Thessaloniki, Thessaloniki, Macedonia, Greece|University General Hospital of Larissa, Larissa, Thessaly, Greece|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Eastern District, Hong Kong|Humanity and Health Research Centre, Central, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Hong Kong United Oncology Centre, Kowloon, Hong Kong|Princess Margaret Hospital, Kowloon, Hong Kong|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli-cesena, Italy|Centro di Riferimento Oncologico di Aviano, Aviano, Pordenone, Italy|Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Istituto Scientifico Universitario San Raffaele, Milano, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Ulsan University Hospital, Ulsan, Gyeongsangnam-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Medica Sur, Ciudad de Mexico, Cdmx, Mexico|Centro de Investigacion Medica Aguascalientes, Aguascalientes, Mexico|Institutul Oncologic Prof. Dr. Ion Chiricu, Cluj-Napoca, Cluj, Romania|Oncocenter- Oncologie Clinic, Timioara, Timis, Romania|Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucaresti, Bucuresti, Romania|Centrul de oncologie Euroclinic, Iasi, Romania|Euromedservice, Saint-Petersburg, Saint Petersburg, Russian Federation|Saint Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Aid, Saint-Petersburg, Saint Petersburg, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|VitaMed, Moscow, Russian Federation|State Budget Institution National Medical Research Center of Radiology of the Ministry of Heal, Moscow, Russian Federation|Moscow City Oncology Hospital Number 62, Moscow, Russian Federation|Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|Center of Palliative Medicine - Devita, Saint Petersburg, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Teresa Herrera - Materno Infantil, A Coruna, LA Coruna, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Karolinska Universitetssjukhuset - Solna, Solna, Stockholm, Sweden|Uppsala Akademiska Sjukhus, Uppsala, Sweden|Changhua Christian Hospital, Changhua City, Taiwan|Hualien Tzu Chi Hospital, Hualien, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Chi Mei Hospital Liouying, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan|Phramongkutklao Hospital, Bangkok, Bangkok Metropolis, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Songklanagarind Hospital, Songkhla, Thailand",,https://ClinicalTrials.gov/show/NCT03596866,2,brigatinib,alectinib,1,1,FALSE,FALSE,FALSE,FALSE,brigatinib,alectinib,1,1,TRUE,
653,2865,2866,NCT03302247,Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,,Terminated,No Results Available,Non Small Cell Lung Cancer Stage IIIB,Biological: Nivolumab|Drug: Nivolumab+Gemcitabine,Evaluate depletion of MDSC in numbers as a result of treatment with gemcitabine.|Evaluate whether these measures result in enhanced T-cell activity|Evaluate whether these measures result in enhanced NK cell function|Determine the tolerability and clinical activity (including response rate and survival) of this approach|Correlate MDSC number with tumor PD-L1 expression,Fox Chase Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TH-113,15-Jan-18,21-Mar-19,12-Jul-19,5-Oct-17,,25-Jul-19,"Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03302247,2,nivolumab,nivolumab+gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,nivolumab,nivolumab+gemcitabine,1,1,TRUE,
655,2869,2870,NCT00754364,Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients,,Terminated,No Results Available,NSCLC,Drug: Pemetrexed/Carboplatin|Drug: Gemcitabine,"Evaluate Progression Free Survival of Carboplatin plus Alimta vs gemcitabine in chemonaive, elderly stage IIIB-IV NSCLC patients.|Overall Survival Quality of life","Armando Santoro, MD|Istituto Clinico Humanitas",All,70 Years and older   (Older Adult),Phase 2,108,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ONC-2007-003,8-Oct,14-May,15-Dec,18-Sep-08,,29-Jan-14,"Istituto Clinco Humanitas, Rozzano, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00754364,2,pemetrexed/carboplatin,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed/carboplatin,gemcitabine,1,1,TRUE,
667,2906,2907,NCT02595840,Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE),Trans-MARBLE,Terminated,No Results Available,Non-small-cell Lung Cancer With Somatic EGFR Mutations,Drug: Afatinib|Drug: Pemetrexed,Progression-free Survival in relation to exploratory biomarkers|Overall Survival in relation to exploratory biomarkers|Objective response rate,Universität Duisburg-Essen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT-Nr. 2014-001983-36,25-Nov-15,20-Nov-17,20-Nov-17,4-Nov-15,,19-Apr-19,,,https://ClinicalTrials.gov/show/NCT02595840,2,afatinib,pemetrexed,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,pemetrexed,1,1,TRUE,
670,2916,2917,NCT00280735,Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC,,Completed,Has Results,Lung Cancer,Drug: carboplatin|Drug: docetaxel,Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen|Patterns of Recurrence in Patients Treated With This Regimen|Toxicity in Patients Treated With This Regimen|Progression Free Survival|Overall Survival,UNC Lineberger Comprehensive Cancer Center|Aventis Pharmaceuticals,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,75,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCCC 0320,4-May,11-Jul,11-Jul,23-Jan-06,12-Jun-17,11-Jul-17,"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00280735,2,carboplatin,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,docetaxel,1,1,TRUE,
671,2931,2932,NCT03810872,"An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation",,Recruiting,No Results Available,"Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation",Drug: Afatinib|Drug: Paclitaxel,Response rate|Incidence and intensity of adverse events|Disease control rate|Progression free survival|Overall survival,AZ-VUB,All,"18 Years and older   (Adult, Older Adult)",Phase 2,87,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Precision 2 - 1200.264,21-Jun-17,20-Dec,22-Dec,21-Jan-19,,21-Jan-19,"Institut Jules Bordet, Brussels, Belgium|Les Cliniques Universitaires St Luc, Brussels, Belgium|Universitaire Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|CHU Sart-Tilman, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT03810872,2,afatinib,paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,paclitaxel,1,1,TRUE,
673,2943,2944,NCT00256711,Phase II Iressa Versus Vinorelbine (INVITE),,Completed,No Results Available,Non-Small-Cell Lung Carcinoma,Drug: Gefitinib|Drug: Vinorelbine,To compare ZD1839 and vinorelbine in terms of progression free survival|To compare ZD1839 and vinorelbine in terms of pulmonary symptom improvement weekly for 18 weeks.|To compare ZD1839 and vinorelbine in terms of quality of life 3 weekly for 18 weeks then 6 weekly.|To compare ZD1839 and vinorelbine in terms of adverse event profile continuous monitoring.|To compare ZD1839 and vinorelbine in terms of overall objective tumour response rate (complete response and partial response) 6 weekly to progression.|To compare ZD1839 and vinorelbine in terms of overall survival (time to death) continuous monitoring,AstraZeneca,All,70 Years and older   (Older Adult),Phase 2,192,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D791AC00001|INVITE,4-Jul,,6-Feb,22-Nov-05,,23-Apr-09,"Research Site, St. Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Victoria, Australia|Research Site, Fortaleza, CE, Brazil|Research Site, Goiania, GO, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Praha 8, CZ, Czech Republic|Research Site, Usti nad Labem, CZ, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Kutná Hora, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava - Poruba, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Marseille Cedex 09, France|Research Site, Montpellier Cedex 5, France|Research Site, Montpellier Cedex, France|Research Site, Pierre Benite Cedex, France|Research Site, Vesoul Cedex, France|Research Site, Heidelberg, Baden-Württemberg, Germany|Research Site, Ulm, Baden-Württemberg, Germany|Research Site, München, Bayern, Germany|Research Site, Magdeburg, Sachsen-Anhalt, Germany|Research Site, Bad Segeberg, Schleswig-Holstein, Germany|Research Site, Berlin, Germany|Research Site, Großhansdorf, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Mainz, Germany|Research Site, La Torretta, Ancona, Italy|Research Site, Bergamo, BG, Italy|Research Site, Bologna, BO, Italy|Research Site, Catania, CT, Italy|Research Site, Melegnano, MI, Italy|Research Site, Milano, MI, Italy|Research Site, Rozzano, MI, Italy|Research Site, Modena, MO, Italy|Research Site, Parma, PR, Italy|Research Site, Orbassano, TO, Italy|Research Site, Torino, TO, Italy|Research Site, Napoli, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Cambridge, Cambrideshire, United Kingdom|Research Site, Birmingham, West Midlands, United Kingdom|Research Site, Aberdeen, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00256711,2,gefitinib,vinorelbine,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,vinorelbine,1,1,TRUE,
689,2996,2997,NCT01523587,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib|Drug: erlotinib,"Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1|Overall Survival|Number of Participants With Objective Response According to RECIST 1.1|Number of Participants With Disease Control According to RECIST 1.1|Tumour Shrinkage|Number of Participants With Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire|Summary of Time to Deterioration in Coughing, Dyspnoea and Pain.|Change in Score Over Time in Coughing,Dyspnoea and Pain",Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,795,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.125|2011-002380-24,5-Mar-12,21-Oct-13,27-Dec-17,1-Feb-12,21-Nov-14,15-Feb-19,"Ironwood Cancer and Research Centers, Chandler, Arizona, United States|University of California, La Jolla, California, United States|Sutter Medical Group, Sacramento, California, United States|Boca Raton Reginl Hospital-Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Cancer Care of North Florida, PA, Lake City, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Orchard Healthcare Research Inc, Skokie, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|West Jefferson General Hospital and Cancer Clinic, Marrero, Louisiana, United States|Lahey Clinic, Burlington, Massachusetts, United States|Commonwealth Hematology-Oncology, PC, Lawrence, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology, Inc, Columbus, Ohio, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oncology Hematology Associates of Norhtern Pennsylvania, PC, DuBois, Pennsylvania, United States|Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Cancer Center, Philadelphia, Pennsylvania, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Cancer Center of Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Paris Cancer Center (PCC), Texas Oncology, Paris, Texas, United States|Cancer Therapy and Research at UTHSCSA, San Antonio, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma de Bs As, Argentina|Instituto Oncologico de Cordoba, Cordoba, Argentina|Clínica Colombo S.A., Cordoba, Argentina|Centro Oncologico de Rosario, Rosario, Argentina|Centro Oncologico CAIPO, San Miguel de Tucuman, Argentina|Medical University of Innsbruck, Innsbruck, Austria|LKH Leoben, Leoben, Austria|AKH d. Stadt Linz, Pulmologie, Linz, Austria|SMZ Baumgartner Hoehe Otto Wagner Spital, Wien, Austria|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|Centro Oncologico Antofagasta, Antofagasta, Chile|Instituto de Terapias Oncologicas Providencia, Providencia, Santiago, Chile|Centro Internacional de Estudios Clinicos - CIEC, Recoleta, Santiago De Chile, Chile|Orlandi Oncologia, Vitacura, Chile|Beijing Cancer Hospital, Beijing, China|Beijing Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital, Central South University, Changsha, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Herlev Hospital, Herlev, Denmark|Næstved Sygehus, Næstved, Denmark|Odense Universitetshospital, Odense C, Denmark|HOP d'Angers, Angers, France|INS Bergonié, Bordeaux, France|HOP Côte de Nacre, Caen, France|HOP de Chauny, Chauny, France|HOP Gabriel-Montpied, Clermont Ferrand, France|HOP de Creteil, Pneumo, Creteil, Creteil, France|HOP Le Mans, Le Mans, France|CTR Oscar Lambret, Cancéro, Lille, Lille, France|HOP Calmette, Lille, France|HOP Nord, Marseille Cedex 20, France|INS Paoli-Calmettes, Marseille, France|HOP de Mulhouse, Onco, Mulhouse, Mulhouse, France|HOP Cochin, Paris, France|HOP Val de Grâce, Onco, Paris, Paris, France|INS Jean Godinot, Onco, Reims, Reims, France|HOP de Rennes, Pneumo, Rennes, Rennes, France|HOP Saint Quentin, Onco, Saint Quentin, Saint Quentin, France|HOP Civil, Strasbourg, France|HOP Foch, Suresnes, France|INS Gustave Roussy, Villejuif, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Universitätsklinikum Münster, Münster, Germany|Mathias-Spital Rheine, Rheine, Germany|""Hippokratio"" Hospital of Athens, 2nd Internal Medicine Clin, Athens, Greece|General Hospital of Chest Diseases Sotiria, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University Hospital of Larisa, Oncology Clinic, Larisa, Greece|General Hospital of Larissa, Larisa, Greece|Metropolitan Hospital, Oncology Clinic, Neo Faliro, Athens, Greece|General Hospital ""G. Papageorgiou"", Thessaloniki, Greece|National Koranyi TBC and Pulm. Internal Med. Clinic, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Institute of Chest Diseases Csongrad County,Dpt. Pulmonology, Deszk, Hungary|Pulmonology Institute of Veszprem County, Farkasgyepu, Farkasgyepü, Hungary|Aladar Petz County Teaching Hospital, Dept. Pulmonology, Györ, Hungary|Lung Hospital of Matra, Dept. Pulmonology, Matrahaza, Hungary|Josa Andras Korhaz, Nyiregyhaza, Nyiregyhaza, Hungary|University of Pecs, 1st internal Med. Dept., Pulmonology, Pecs, Hungary|Pest County Lung Hospital, Department No. 3, Törökbalint, Hungary|Vikram Hospital, Bangalore, India|V S Hospital, Chennai, India|Dr. Kamakshi Memorial Hospital, Chennai, India|Sri Ramachandra Medical College & Research Institute, Chennai, India|M.S. Patel Cancer Hospital, Karamsad, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|Tata Memorial Hospital, Mumbai, India|Ruby Hall Clinic, Pune, India|St James's Hospital, Dublin 8, Ireland|P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna, Bologna, Italy|ASST di Cremona, Cremona, Italy|Spedali Riuniti di Livorno, Livorno, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliera di Parma, Parma, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedale San Vincenzo, Taormina (ME), Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|A. O. S. Maria della Misericordia, Udine, Italy|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vincent's Hospital, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Mexico|Hospital y Clínica OCA S. A. de C. V., Monterrey, Mexico|Centro Hemato-Oncologico Privado de Toluca S.A. de C.V., Toluca, Mexico|Jeroen Bosch Ziekenhuis-Hertogenbosch, 's-HERTOGENBOSCH, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|METC Academisch Ziekenhuis Maastricht/Universiteit van Maastricht, Maastricht, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|National Cancer Centre, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Hospital A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Chang Gung Memorial Hospital Chiayi, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Bursa, Turkey|Dicle Universitesi Tip Fakultesi, Diyarbakir, Turkey|Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali, Gaziantep, Turkey|Kartal Egitim Ve Arastirma Hastanesi, Istanbul, Turkey|Yedikule Gog. Hst. EAH, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali, Izmir, Turkey|Dr.Suat Seren EAH, Izmir, Turkey|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Harrogate District Hospital, Harrogate, United Kingdom|Royal Free Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Maidstone Hospital, Kent Oncology Centre, Maidstone, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Scarborough Hospital, Scarborough, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01523587/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01523587/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01523587,2,afatinib,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,erlotinib,1,1,TRUE,
694,3005,3006,NCT00003117,Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: paclitaxel,,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,584,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CALGB-9730|U10CA031946|CLB-9730|CDR0000065871,Oct-97,4-Dec,6-Jan,19-May-04,,30-Jun-16,"University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Mount Sinai Medical Center, NY, New York, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Vermont Cancer Center, Burlington, Vermont, United States|Massey Cancer Center, Richmond, Virginia, United States|MBCCOP - Massey Cancer Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00003117,2,carboplatin,paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,paclitaxel,1,1,TRUE,
695,3008,3009,NCT02151149,Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly,ABOUND 70+,Completed,Has Results,"Non-Small Cell Lung Cancer|Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Large Cell|Lung Neoplasm",Drug: nab-paclitaxel|Drug: Carboplatin,Percentage of Participants With Either Peripheral Neuropathy ≥ Grade 2 or Myelosuppression Adverse Events (AEs) ≥ Grade 3 Based on Local Laboratory Values|Number of Participants With Treatment Emergent Adverse Events During the Treatment Period|Percentage of Participants With at Least 1 Treatment Emergent Adverse Event With Action Taken as Study Drug Withdrawn|Dose Intensity Per Week of Nab-Paclitaxel During the Entire Study|Dose Intensity Per Week of Carboplatin During the Entire Study|Percentage of Participants With Dose Reductions During the Entire Study|Percentage of Participants With a Dose Delay During the Entire Study|Kaplan Meier Estimate of Progression-Free Survival (PFS)|Kaplan Meier Estimate of Overall Survival (OS)|Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 Criteria,Celgene,All,70 Years and older   (Older Adult),Phase 4,143,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ABI-007-NSCL-005,9-Jun-14,14-Jul-17,14-Jul-17,30-May-14,24-Sep-18,24-Sep-18,"Arizona Clinical Research Center, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Saint Jude Heritage Medical Center, Fullerton, California, United States|Global Cancer Research Institute (GCRI), Inc., Gilroy, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|University of California Los Angeles, Santa Monica, California, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|St Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Baptist Cancer Inst, Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Northshore University Healthsystem Research Institute, Evanston, Illinois, United States|Oncology Specialists, S.C., Niles, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Western Kentucky Hematology and Oncology Group, Paducah, Kentucky, United States|West Jeffersion Medical Center, Marrero, Louisiana, United States|Ochsner Medical Institutions, New Orleans, Louisiana, United States|Medstar Health Research Institute, Baltimore, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Carol G Simon Cancer Center, Morristown, New Jersey, United States|Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States|Regional Cancer Care Associates LLC- Sparta division, Sparta, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|SUNY Upstate Medical University Medicine Oncology, Syracuse, New York, United States|Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Forsyth Memorial Hospital, Inc., Winston-Salem, North Carolina, United States|St Elizabeth Hospital, Youngstown, Ohio, United States|Cancer Centres of Southwest Okahoma Research, Lawton, Oklahoma, United States|Good Samaritan Hospital Corvalis, Corvallis, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Texas Oncology, PA - Longview, Longview, Texas, United States|Virginia Mason Cancer Center, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States","""Statistical Analysis Plan: ABI-007-NSCL-005_SAP_AM!_Redacted.17March 2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_000.pdf|""Study Protocol: ABI-007-NSCL-005_PA1_Redacted.09April2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_001.pdf|""Statistical Analysis Plan: ABI-007-NSCL-005.OriginalSAP.Redacted24 June2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/SAP_002.pdf|""Study Protocol: ABI-007-NSCL-005_PA2_Redacted.05 December 2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_003.pdf|""Study Protocol: ABI-007-NSCL-005_PA3_Redacted.17 March 2016"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_004.pdf|""Study Protocol: ABI-007-NSCL-005_Original_Redacted.06 March2014"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02151149/Prot_005.pdf",https://ClinicalTrials.gov/show/NCT02151149,2,nab-paclitaxel,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,nab-paclitaxel,carboplatin,1,1,TRUE,
701,3033,3034,NCT00043823,Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: Avastin|Drug: Tarceva,Maximum Tolerated Dose (MTD) of Tarceva in combination with Avastin|Response in Patients With NSCLC Receiving Combination Avastin and Tarceva,"M.D. Anderson Cancer Center|Genentech, Inc.|Vanderbilt-Ingram Cancer Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,41,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ID01-604|VICC THO 0206,1-Aug-02,15-May-06,15-May-06,15-Aug-02,,7-Nov-18,"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00043823,2,avastin,tarceva,1,1,FALSE,FALSE,FALSE,FALSE,avastin,tarceva,1,1,TRUE,
711,3061,3062,NCT02303977,Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy,,Recruiting,No Results Available,Patients With Stage IV or Recurrent Adenocarcinoma of the Lung,Drug: Abraxane|Drug: Gemcitabine,Number of Adverse Events,Abramson Cancer Center of the University of Pennsylvania,All,"18 Years and older   (Adult, Older Adult)",Phase 2,37,Other,Interventional,Primary Purpose: Treatment,UPCC 21514,14-Nov,19-Apr,,1-Dec-14,,21-Aug-18,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02303977,2,abraxane,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,abraxane,gemcitabine,1,1,TRUE,
714,3066,3067,NCT02289456,Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2,AboundPS2,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: nab-Paclitaxel|Drug: Carboplatin,Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).|Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)|Dose Intensity of Nab-Paclitaxel During the Entire Study|Dose Intensity of Carboplatin During the Entire Study|Percentage of Participants With Dose Reductions During the Entire Study|Kaplan Meier Estimate of Progression-Free Survival (PFS)|Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)|Kaplan Meier Estimate of Overall Survival (OS)|Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines|Time to Response|Kaplan Meier Estimate of Duration of Response|Number of Participants With TEAEs During the Induction and Monotherapy Periods,Celgene,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ABI-007-NSCL-004,28-Apr-15,22-Feb-17,22-Feb-17,13-Nov-14,24-Apr-18,7-Dec-18,"University Cancer Institute, Boynton Beach, Florida, United States|Ochsner Clinic Nephrology, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|University of RochesterJames P. Wilmont Cancer Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/SAP_000.pdf|""Study Protocol: ABI-007-NSCL-004ProtocolAm1RedactedFinal.12Jan 2015"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/Prot_001.pdf|""Study Protocol: ABI-007-NSCL-004.OriginalProtocolRedacted11Aug2014"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02289456/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT02289456,2,nab-paclitaxel,carboplatin,1,1,FALSE,FALSE,FALSE,FALSE,nab-paclitaxel,carboplatin,1,1,TRUE,
715,3069,3070,NCT01562028,BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC),BELIEF,Completed,Has Results,Lung Cancer,Drug: Erlotinib|Drug: Bevacizumab,Progression Free Survival|Overall Survival|Time to Treatment Failure|Objective Response|Disease Control|Duration of Response|Adverse Events,European Thoracic Oncology Platform|Spanish Lung Cancer Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,109,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ETOP 2-11 / MO27911|2011-004481-15|MO27911,12-Jun,31-Oct-18,31-Oct-18,23-Mar-12,31-Oct-19,31-Oct-19,"Centre Francois Baclesse, Caen, France|Hôpital de Marseille, Marseille, France|Hospital Grosshansdorf, Grosshansdorf, Germany|Thoraxklinik Heidelberg GmbH, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinikum Ulm, Ulm, Germany|University General Hospital of Heraklion, Heraklion, Greece|Papageorgias Hospital, Thessaloniki, Greece|St Vincent's University Hospital, Dublin, Ireland|St. James's Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Mid-Western Regional Hospital, Limerick, Ireland|AMCCH, Tallaght, Ireland|Ospedale San Gerardo, Monza, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Casa di Cura Maddalena, Palermo, Italy|Policlinico Tor Vergata Roma, Roma, Italy|San Camillo Hospital, Roma, Italy|Policlinico Umberto, Roma, Italy|Hospital General Universitario Alicante, Alicante, Spain|ICO - Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Vall d'Hebron University Hospital, Barcelona, Spain|Hospital Clínic Barcelona, Barcelona, Spain|ICO - Girona, Girona, Spain|ICO - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain|Hospital Clinico Universitario San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Istituto Oncologica della Svizzera Italiana, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Geneva University Hospital, Geneva, Switzerland|Fondation du centre Pluridisciplinaire d'Oncologie (CePO), Lausanne, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Onkologiezentrum Berner Oberland, Thun, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|University Hospital Zurich, Zurich, Switzerland|Mid Essex Hospital Services NHS Trust, Chelmsford, Essex, United Kingdom|Queen's Hospital, Burton-upon-Trent, United Kingdom|University Hospitals of Leicester, Leicester, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Kent Oncology Centre, Maidstone, United Kingdom|Christie Hospital Manchester, Manchester, United Kingdom|Wythenshawe Hospital Manchester, Manchester, United Kingdom|Wrexham Maelor Hospital, Wrexham, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01562028/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01562028/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01562028,2,erlotinib,bevacizumab,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,bevacizumab,1,1,TRUE,
719,3080,3081,NCT02625168,Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC,,Completed,No Results Available,Lung Cancer,Drug: Afatinib|Drug: Erlotinib,Progression-free survival|Objective response rate|Overall survival|Toxicity profiles,The University of Hong Kong,All,"Child, Adult, Older Adult",Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Version 1,13-Jan,14-Sep,14-Dec,9-Dec-15,,9-Dec-15,"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02625168,2,afatinib,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,erlotinib,1,1,TRUE,
727,3119,3120,NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,LUX-Lung IO,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Afatinib|Drug: pembrolizumab,Objective Response (OR)|Disease control (DC)|Duration of objective response (DoR)|Progression-free survival (PFS)|Overall survival (OS)|Tumour shrinkage (in millimeters)|Recommended Phase II Dose (RP2D),Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200-0283|2016-005042-37,2-Nov-17,18-May-20,18-Jun-20,17-May-17,,30-Oct-19,"Baptist Health Medical Group, Lexington, Kentucky, United States|HOP Côte de Nacre, Caen, France|HOP Le Mans, Le Mans, France|HOP Nord, Marseille, France|HOP Nord Laënnec, Nantes, France|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Vall d'Hebron, Barcelona, Spain|Complejo Hospitalario Universitario Insular - Materno Infantil, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hacettepe Universitesi Tip Fakultesi, Onkoloji ABD, Ankara, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT03157089,2,afatinib,pembrolizumab,1,1,FALSE,FALSE,FALSE,FALSE,afatinib,pembrolizumab,1,1,TRUE,
736,3155,3156,NCT01121393,BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC),,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Drug: Gemcitabine+Cisplatin|Drug: BIBW 2992,Progression-free Survival|Objective Response (OR)|Disease Control (DC)|Overall Survival (OS)|Time to Objective Response (OR)|Duration of Objective Response|Duration of Disease Control|Tumour Shrinkage|Change From Baseline in Body Weight|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Health Related Quality of Life (HRQOL): Time of Deterioration in Coughing|Health Related Quality of Life (HRQOL): Time of Deterioration in Dyspnoea|Health Related Quality of Life (HRQOL): Time of Deterioration in Pain|Pharmacokinetics of Afatinib at Day 22|Pharmacokinetics of Afatinib at Day 29|Pharmacokinetics of Afatinib at Day 43|Safety of Afatinib as Indicated by Intensity and Incidence of Adverse Events|Changes in Safety Laboratory Parameters,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",Phase 3,364,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1200.34,19-Apr-10,23-Nov-17,26-Nov-17,12-May-10,26-Jan-15,14-Dec-18,"Beijing Chao-Yang Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Beijing Chest Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital, Central South University, Changsha, China|Hunan Province Tumor Hospital, Changsha, China|West China Hospital, Chengdu, China|Fujian Provincial Tumor Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, China|Guangzhou Institute of Respiratory Disease, Guangzhou, China|NanFang Hosptial, Guangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Haerbin, China|Zhejiang Cancer Hospital, Hangzhou, China|Hubei Cancer Hospital, HongShan, China|Yunnan Provincial Tumor Hospital, Kunming, China|Lin Yi Tumor Hospital, Linyi, China|The Affiliated Cancer Hospital, Guangxi Medical University, Nan Ning, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai Chest Hospital, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Changhai Hospital, Shanghai, China|The First Hospital of Chinese Medical University, Shenyang, China|Hebei Provincial Tumor Hospital, Shijiazhuang, China|Tangdu Hospital, Xi'An, China|Northern Jiangsu People's Hospital, Yangzhou, China|Kosin University Gospel Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Songklanagarind Hospital, Songkla, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01121393/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01121393/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01121393,2,gemcitabine+cisplatin,bibw 2992,1,1,FALSE,FALSE,FALSE,FALSE,gemcitabine+cisplatin,afatinib,1,1,FALSE,Cisplatin is not an approved drug
744,3178,3179,NCT00061464,Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.,,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: pemetrexed|Drug: gemcitabine,To determine the tumor response rate for pemetrexed plus gemcitabine in patients with locally advanced or metastatic (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC).|To measure time-to-event efficacy variables including:|time to objective tumor response for responding patients|duration of response for responding patients|time to treatment failure|time to progressive disease|progression-free survival|overall survival|To characterize the quantitative and qualitative toxicities of pemetrexed plus gemcitabine in this patient population.,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7211|H3E-US-JMFX,3-Feb,,6-Feb,29-May-03,,26-Jan-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00061464,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
750,3196,3197,NCT00071136,Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Lung Neoplasms,Drug: pemetrexed|Drug: gemcitabine,To find out how often tumors become smaller or disappear in patients with advanced NSCLC treated with gemcitabine followed by pemetrexed once every 14 days. Chemotherapy treatment will be given for up to 12 times or until the cancer disease increases.|To measure the effects of chemotherapy treatment on:|time until the cancer becomes less;time to cancer re-appears or becomes larger;length of time there is no increase in the amount of cancer;length of time patients survive;|To measure the side-effects from this chemotherapy as given once every 14 days.,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7221|H3E-US-JMGC,3-Dec,,6-Aug,16-Oct-03,,26-Jan-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Ft. Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Marshfield, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Rochester, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT00071136,2,pemetrexed,gemcitabine,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,gemcitabine,1,1,TRUE,
752,3217,3218,NCT01757288,"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC",,"Active, not recruiting",No Results Available,STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER,Drug: NAB-PACLITAXEL|Drug: PACLITAXEL,"2-year overall survival from randomization for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the feasibility of concurrent carboplatin/nab-paclitaxel and radiation therapy|overall response rate for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the progression-free survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|the median overall survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy|quality of life (QOL) of patients receiving either nab-paclitaxel or paclitaxel when given with concurrent radiotherapy|correlate outcomes (survival, toxicity, QOL) with biological parameters",University of Texas Southwestern Medical Center|Celgene,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,98,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 062012-053,25-Mar-13,20-Feb,21-Feb,28-Dec-12,,8-Mar-19,"University of Rochester, Rochester, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01757288,2,nab-paclitaxel,paclitaxel,1,1,FALSE,FALSE,FALSE,FALSE,nab-paclitaxel,paclitaxel,1,1,TRUE,
756,3249,3250,NCT02328105,LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer,,"Active, not recruiting",Has Results,Lung Cancer,Drug: Carboplatin|Drug: Abraxane,Number of Participants With a Response|Number of Subjects With Stable Disease or Response|Progression Free Survival|Overall Survival|Duration of Response|Duration of Disease Control,Kathryn Mileham|Celgene|Atrium Health,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCI-LUN-ABR-001|00010224,14-Dec,15-Jun-17,19-Nov,31-Dec-14,11-Jul-18,25-Jul-19,"Levine Cancer Institute, Charlotte, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02328105/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02328105,2,carboplatin,abraxane,1,1,FALSE,FALSE,FALSE,FALSE,carboplatin,abraxane,1,1,TRUE,
758,3260,3261,NCT00470548,Abraxane and Alimta in Advanced Solid Tumors,,Terminated,Has Results,"Breast Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Abraxane|Drug: Alimta,Number of Participants With Dose Limiting Toxicities|Number of Patients With Toxicities|Duration of Overall Survival|Number of Participants With Complete Response|Number of Participants With Stable Disease|Number of Participants With Partial Response|Number of Participants With Disease Control,"University of California, Davis|Celgene|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,49,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UCDCC#185|224355|ABX027|H3E-US-I017,7-Apr,14-Oct,14-Oct,7-May-07,8-Mar-17,10-Jan-18,"University of California Davis Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00470548,2,abraxane,alimta,1,1,FALSE,FALSE,FALSE,FALSE,abraxane,alimta,1,1,TRUE,
763,3290,3291,NCT02443324,"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",,"Active, not recruiting",No Results Available,"Gastric Adenocarcinoma|Adenocarcinoma of the Gastroesophageal Junction|Non-small Cell Lung Cancer|Carcinoma, Transitional Cell|Biliary Tract Cancer",Drug: Ramucirumab|Drug: Pembrolizumab,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Proportion of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]|Proportion of Participants who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]|Duration of Response (DoR)|Time to First Response (TTR)|Progression Free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,Eli Lilly and Company|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,155,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15787|I4T-MC-JVDF|2015-001473-40|KEYNOTE -098,29-Jul-15,31-Aug-18,28-Feb-20,13-May-15,,5-Aug-19,"Yale University School of Medicine, New Haven, Connecticut, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Tennessee Oncology PLLC, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon Cedex 08, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris CEDEX 05, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi-Shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamanashi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02443324,2,ramucirumab,pembrolizumab,1,1,FALSE,FALSE,FALSE,FALSE,ramucirumab,pembrolizumab,1,1,TRUE,
775,3353,3354,NCT00447057,Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC),,Completed,Has Results,Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.,Drug: Pemetrexed|Drug: Erlotinib,"Progression Free Survival (PFS)|Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)|Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)|Time to Treatment Failure (TTTF)|Overall Survival (OS)|Percentage of Participants Surviving at 1 Year|Number of Participants With Adverse Events (AEs)",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,204,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,10721|H3E-MC-S102,7-Mar,10-Jul,11-Jun,13-Mar-07,13-Oct-11,13-Oct-11,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salzburg, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gauting, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gerlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trier, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deszk, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matrahaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szekesfehervar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linkoping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden",,https://ClinicalTrials.gov/show/NCT00447057,2,pemetrexed,erlotinib,1,1,FALSE,FALSE,FALSE,FALSE,pemetrexed,erlotinib,1,1,TRUE,
778,3367,3368,NCT03611738,"Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC",,Recruiting,No Results Available,Non-small Cell Lung Cancer|Lung Cancer|Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB|Stage IV Non-small Cell Lung Cancer|EGFR Negative Non-Small Cell Lung Cancer,Drug: Ceritinib|Drug: Docetaxel,Phase I: Maximum Tolerated Dose (MTD)|Phase Ib: Overall Response (OR)|Progression-free Survival (PFS)|Overall Survival (OS),H. Lee Moffitt Cancer Center and Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-19656,31-Oct-18,23-Oct,24-Oct,2-Aug-18,,3-Oct-19,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT03611738,2,ceritinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,ceritinib,docetaxel,1,1,TRUE,
781,3373,3374,NCT00478049,Iressa as Second Line Therapy in Advanced NSCLC-Asia,ISTANA,Completed,No Results Available,NSCLC,Drug: Gefitinib|Drug: Docetaxel,Compare progression free survival between patients on gefitinib or on docetaxel by Progression as per Response Evaluation Criteria In Solid Tumors|To compare the overall objective tumor response rates between patients on gefitinib or on docetaxel by overall objective tumor response (complete response (CR) + partial response (PR)) using RECIST criteria.|To compare changes in quality of life (QoL) between patients on gefitinib or on docetaxel by QoL as measured by the FACT-L total score|For those patients who are symptomatic at baseline to compare improvement in symptom control between patients on gefitinib or on docetaxel by the FACT-L LCS (Functional Assessment of Cancer Therapy - Lung Lung Cancer Subscale).|To compare the safety and tolerability of gefitinib and of docetaxel by Frequency and severity of adverse events (AEs) and laboratory parameters.,AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 3,163,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D7913L00039,5-Sep,7-May,9-Feb,24-May-07,,6-Jun-12,"Research Site, In Cheon, Korea, Republic of|Research Site, Kyonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00478049,2,gefitinib,docetaxel,1,1,FALSE,FALSE,FALSE,FALSE,gefitinib,docetaxel,1,1,TRUE,
786,3396,3397,NCT02454933,Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,CAURAL,"Active, not recruiting",Has Results,Locally Advanced or Metastatic EGFR T790M+ NSCLC,Drug: AZD9291|Drug: MEDI4736,Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab,AstraZeneca,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,29,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5165C00001,15-Jul-15,21-Aug-17,20-Dec-19,27-May-15,10-Aug-18,4-Sep-19,"Research Site, Toronto, Ontario, Canada|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02454933/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02454933/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02454933,2,azd9291,medi4736,1,1,FALSE,FALSE,FALSE,FALSE,tagrisso,durvalumab,1,1,TRUE,
808,3538,3539,NCT03340506,Dabrafenib and/or Trametinib Rollover Study,,Recruiting,No Results Available,Melanoma|Non Small Cell Lung Cancer|Solid Tumor|Rare Cancers|High Grade Glioma,Drug: dabrafenib|Drug: trametinib,"Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination|Clinical Benefit Assessment by investigator",Novartis Pharmaceuticals|Novartis,All,"Child, Adult, Older Adult",Phase 4,100,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDRB436X2X02B,28-Dec-17,17-Jul-23,17-Jul-23,13-Nov-17,,29-Aug-19,"Honor Health Research Institute, Scottsdale, Arizona, United States|James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Songkla, Thailand",,https://ClinicalTrials.gov/show/NCT03340506,2,dabrafenib,trametinib,1,1,FALSE,FALSE,FALSE,FALSE,dabrafenib,trametinib,1,1,TRUE,
811,3545,3546,NCT01024413,Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations,,Completed,No Results Available,Thoracic Neoplasms,Drug: erlotinib|Drug: gefitinib,progression-free survival|overall survival|Safety events|Pharmacoeconomic|Response rate,Chinese Society of Lung Cancer|Guangdong Provincial People's Hospital,All,"Child, Adult, Older Adult",Phase 3,256,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-TONG0901,9-Jul,15-Jun,15-Jun,2-Dec-09,,1-Mar-17,"Guangdong General Hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01024413,2,erlotinib,gefitinib,1,1,FALSE,FALSE,FALSE,FALSE,erlotinib,gefitinib,1,1,TRUE,
832,3674,3675,NCT02572687,A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,,"Active, not recruiting",No Results Available,Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Non-Small Cell Lung Cancer|Hepatocellular Carcinoma,Drug: Ramucirumab|Drug: MEDI4736,"Number of Participants with Dose Limiting Toxicities (DLTs)|Percentage of Participants with a Best Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)|Proportion of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)|Duration of Response (DoR)|Time to First Response (TTR)|Progression Free Survival (PFS)|Overall Survival (OS)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab and MEDI4736|PK: Minimum Concentration (Cmin) of Ramucirumab and MEDI4736|Number of Participants with Treatment Emergent Anti Ramucirumab Antibodies|Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies",Eli Lilly and Company|AstraZeneca,All,"18 Years and older   (Adult, Older Adult)",Phase 1,114,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16116|I4T-MC-JVDJ|2015-003013-14,19-Feb-16,27-Mar-18,27-Mar-20,9-Oct-15,,5-Aug-19,"UCLA Medical Center, Santa Monica, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|The Miriam Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille Cedex 5, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier Cedex 5, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne Cedex 2, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|Hadassah Medical Center - Ein Karem, Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rozzano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malaga, Spain|Hospital Virgen del Rocío, Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02572687,2,ramucirumab,medi4736,1,1,FALSE,FALSE,FALSE,FALSE,ramucirumab,durvalumab,1,1,TRUE,